KR20180036167A - Composition for increasing muscular strength and muscle mass comprising bean juice-peptides derived from germinated bean treated with green mandarin water - Google Patents
Composition for increasing muscular strength and muscle mass comprising bean juice-peptides derived from germinated bean treated with green mandarin water Download PDFInfo
- Publication number
- KR20180036167A KR20180036167A KR1020160126419A KR20160126419A KR20180036167A KR 20180036167 A KR20180036167 A KR 20180036167A KR 1020160126419 A KR1020160126419 A KR 1020160126419A KR 20160126419 A KR20160126419 A KR 20160126419A KR 20180036167 A KR20180036167 A KR 20180036167A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- weight
- less
- muscle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- 210000003205 muscle Anatomy 0.000 title claims abstract description 39
- 230000001965 increasing effect Effects 0.000 title claims abstract description 10
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims description 21
- 244000046052 Phaseolus vulgaris Species 0.000 title claims description 21
- 241001672694 Citrus reticulata Species 0.000 title claims description 6
- 230000003387 muscular Effects 0.000 title abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 48
- 239000000284 extract Substances 0.000 claims abstract description 111
- 244000068988 Glycine max Species 0.000 claims abstract description 63
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 62
- 239000007788 liquid Substances 0.000 claims abstract description 52
- 241000207199 Citrus Species 0.000 claims abstract description 50
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 49
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 45
- 241000196324 Embryophyta Species 0.000 claims abstract description 30
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 13
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 40
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- 230000006872 improvement Effects 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 210000000663 muscle cell Anatomy 0.000 claims description 15
- 235000020712 soy bean extract Nutrition 0.000 claims description 15
- 206010028289 Muscle atrophy Diseases 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 210000000577 adipose tissue Anatomy 0.000 claims description 9
- 230000026731 phosphorylation Effects 0.000 claims description 9
- 238000006366 phosphorylation reaction Methods 0.000 claims description 9
- 201000000585 muscular atrophy Diseases 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 7
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 claims description 6
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 6
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 6
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 6
- 239000004571 lime Substances 0.000 claims description 6
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000555678 Citrus unshiu Species 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 208000029549 Muscle injury Diseases 0.000 claims description 4
- 240000006909 Tilia x europaea Species 0.000 claims description 4
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 3
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims description 3
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 claims description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 3
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 3
- 206010065941 Central obesity Diseases 0.000 claims description 3
- 240000004307 Citrus medica Species 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims description 3
- 235000000484 citronellol Nutrition 0.000 claims description 3
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229930007744 linalool Natural products 0.000 claims description 3
- 229940116411 terpineol Drugs 0.000 claims description 3
- 230000014616 translation Effects 0.000 claims description 3
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000001243 protein synthesis Methods 0.000 claims description 2
- 240000000560 Citrus x paradisi Species 0.000 claims 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 claims 1
- 244000183685 Citrus aurantium Species 0.000 claims 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 240000008790 Musa x paradisiaca Species 0.000 claims 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 9
- 208000029578 Muscle disease Diseases 0.000 abstract description 3
- 230000007103 stamina Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 230000035784 germination Effects 0.000 description 21
- 239000012153 distilled water Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000002070 germicidal effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 150000005693 branched-chain amino acids Chemical class 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 8
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 238000007654 immersion Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- 240000007087 Apium graveolens Species 0.000 description 4
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 4
- 235000010591 Appio Nutrition 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 229950001002 cianidanol Drugs 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940094952 green tea extract Drugs 0.000 description 4
- 235000020688 green tea extract Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037237 body shape Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000600068 Citrus garrawayi Species 0.000 description 2
- 244000175448 Citrus madurensis Species 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 244000057094 Microcitrus australasica Species 0.000 description 2
- 235000016644 Microcitrus garrowayae Nutrition 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 101100016034 Nicotiana tabacum APIC gene Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000219833 Phaseolus Species 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 240000007313 Tilia cordata Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001319 headspace solid-phase micro-extraction Methods 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- WMOPMQRJLLIEJV-IUODEOHRSA-N (+)-gamma-eudesmol Chemical compound C1[C@H](C(C)(C)O)CC[C@@]2(C)CCCC(C)=C21 WMOPMQRJLLIEJV-IUODEOHRSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LHYHMMRYTDARSZ-GBJTYRQASA-N (-)-alpha-Cadinol Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CC[C@@](C)(O)[C@@H]21 LHYHMMRYTDARSZ-GBJTYRQASA-N 0.000 description 1
- LKKDASYGWYYFIK-UHFFFAOYSA-N (-)-cryptomeridiol Natural products C1CCC(C)(O)C2CC(C(C)(O)C)CCC21C LKKDASYGWYYFIK-UHFFFAOYSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WMOPMQRJLLIEJV-UHFFFAOYSA-N 7-epi-gamma-eudesmanol Natural products C1C(C(C)(C)O)CCC2(C)CCCC(C)=C21 WMOPMQRJLLIEJV-UHFFFAOYSA-N 0.000 description 1
- 235000000073 Amphicarpaea bracteata Nutrition 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- 241000913863 Amphicarpaea edgeworthii Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000176051 Apios tuberosa Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 235000010773 Cajanus indicus Nutrition 0.000 description 1
- 244000105627 Cajanus indicus Species 0.000 description 1
- 241000220451 Canavalia Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 241000682938 Citrus australis Species 0.000 description 1
- 241001292310 Citrus glauca Species 0.000 description 1
- 241001018092 Citrus gracilis Species 0.000 description 1
- 241001018070 Citrus inodora Species 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 235000001938 Citrus medica Nutrition 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000009088 Citrus pyriformis Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 241001018067 Citrus warburgiana Species 0.000 description 1
- 241001018072 Citrus wintersii Species 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241000522215 Dipteryx odorata Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LLKXNMNOHBQSJW-UHFFFAOYSA-N Elemol Natural products CCC(=C)C1CC(C=CC1(C)C)C(C)(C)O LLKXNMNOHBQSJW-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 235000017316 Fortunella japonica Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 235000010666 Lens esculenta Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001627205 Leuconostoc sp. Species 0.000 description 1
- 235000010653 Lupinus angustifolius Nutrition 0.000 description 1
- 240000005776 Lupinus angustifolius Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000002319 Microcitrus Nutrition 0.000 description 1
- 235000000227 Microcitrus australasica Nutrition 0.000 description 1
- 235000008211 Microcitrus australis Nutrition 0.000 description 1
- 235000000226 Microcitrus inodora Nutrition 0.000 description 1
- 235000000225 Microcitrus papuana Nutrition 0.000 description 1
- 235000000224 Microcitrus warburgiana Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 1
- 244000100170 Phaseolus lunatus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000008301 Rhynchosia minima Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 244000038652 Vicia angustifolia Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010716 Vigna mungo Nutrition 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- LHYHMMRYTDARSZ-BYNSBNAKSA-N alpha-cadinol Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CC[C@@](C)(O)[C@@H]21 LHYHMMRYTDARSZ-BYNSBNAKSA-N 0.000 description 1
- DMVUUDMWVRKRFV-UHFFFAOYSA-N alpha-cadinol Natural products CC(O)C1CCC(C)(C)C2CCC(=CC12)C DMVUUDMWVRKRFV-UHFFFAOYSA-N 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- GFJIQNADMLPFOW-UHFFFAOYSA-N cis-Elemol Natural products CC(=C)C1CC(C(C)(C)O)CCC1(C)C=C GFJIQNADMLPFOW-UHFFFAOYSA-N 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- GFJIQNADMLPFOW-VNHYZAJKSA-N elemol Chemical compound CC(=C)[C@@H]1C[C@H](C(C)(C)O)CC[C@@]1(C)C=C GFJIQNADMLPFOW-VNHYZAJKSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012132 radioimmunoprecipitation assay buffer Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- VMSRVIHUFHQIAL-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate Chemical compound [Na+].CN(C)C([S-])=S VMSRVIHUFHQIAL-UHFFFAOYSA-M 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- LHYHMMRYTDARSZ-YJNKXOJESA-N t-cadinol Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CC[C@](C)(O)[C@@H]21 LHYHMMRYTDARSZ-YJNKXOJESA-N 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- FCSRUSQUAVXUKK-VNHYZAJKSA-N α-Eudesmol Chemical compound C1C[C@@H](C(C)(C)O)C[C@H]2C(C)=CCC[C@@]21C FCSRUSQUAVXUKK-VNHYZAJKSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Abstract
Description
본 명세서는 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩의 추출물을 유효성분으로 포함하는 근력 강화 또는 근육량 증진용 조성물에 관한 것이다.The present invention relates to a composition for enhancing muscle strength or muscle mass comprising, as an active ingredient, a liquid obtained from immature fruit of a plant of the genus Citrus (Citrus) or an extract of soybeans treated with the composition.
과체중자이거나 비만인 혹은 정상체중이지만 체지방량이 높은 사람의 경우, 근육량을 증대시키고 체지방을 감소시킴으로써 당뇨, 고혈압 등의 대사성 증후군을 예방 및 치료할 수 있으며, 근육량의 증대로 기초대사 에너지가 증가되어 요요현상 없는 효율적인 다이어트가 가능하다. 근육량의 증대를 위해서는 운동, 식이요법 및 운동능력 향상 보조제 (ergogenic aids) 등이 사용되고 있으며, 운동능력 향상을 위한 기능성 식품과 관련된 연구는 동서양을 막론하고 활발하게 수행되고 있다. 한편, 스테로이드, 카페인, 탄산수소나트륨 및 구연산나트륨 등과 같은 화학적 화합물을 포함하는 보조제는 일정량 이상 복용하면 운동 수행능력을 현저히 증가시킬 수 있으나 상기와 같은 약물은 치명적인 부작용을 수반하여 궁극적으로 건강을 해치게 되는 부작용이 따를 수 있다. 최근에는 이러한 화학적 합성품이 아닌 식물 추출물과 같이 부작용은 적으면서 안정성이 높은 천연물을 이용하여 기능식품을 개발하고자 하는 연구가 활발히 진행되고 있다.In the case of overweight or obese people or people with normal body weight but high body fat, metabolic syndrome such as diabetes and hypertension can be prevented and treated by increasing muscle mass and decreasing body fat. Basal metabolism energy is increased due to increase of muscle mass, Efficient diet is possible. In order to increase muscle mass, exercise, diet and ergogenic aids have been used, and studies related to functional foods for improving athletic performance have been actively conducted, both east and west. On the other hand, supplements containing chemical compounds such as steroids, caffeine, sodium hydrogencarbonate and sodium citrate may significantly increase exercise performance when taken over a certain amount, but such drugs may lead to fatal health problems Side effects may follow. In recent years, studies have been actively carried out to develop functional foods using natural substances having high safety, while having few side effects such as plant extracts, rather than chemical synthetic products.
콩은 아시아 등 여러 지역에서 오랜 기간 동안 전통적인 음식 재료로 소비되어 온 식물로서, 콩 자체 또는 이를 가공한 다양한 제품이 개발되고 있으나, 콩의 주요 영양소의 품질적, 기능적 가치를 증진시키는 기술 등에 대해서는 연구가 미흡한 실정이다. Soybean has been consumed as a traditional food material for a long time in various regions such as Asia, and soybean itself or a variety of processed products thereof have been developed. However, the technology for improving the quality and functional value of the main nutrients of soybean .
본 명세서는 천연물질인 시트러스 속 미숙 과실 유래의 액체를 통해 콩을 처리하고 이를 통해 근력 강화 또는 근육량 증진용 조성물, 대사증후군 개선용 조성물 등을 제공하기 위한 목적을 가진다. The present invention has a purpose to provide a composition for improving muscular strength or muscle mass, a composition for improving metabolic syndrome, etc., by treating soybean through a liquid derived from an immature fruit of the genus Citrus, a natural substance.
상기의 과제를 해결하기 위하여, 본 발명은 일 측면에서 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩의 추출물을 유효성분으로 포함하는 근력 강화 또는 근육량 증진용 조성물을 제공한다.In order to solve the above problems, the present invention provides, in one aspect, a composition for enhancing muscle strength or muscle mass comprising, as an active ingredient, a liquid obtained from immature fruit of a plant of the genus Citrus or an extract of soybeans treated with the processed product do.
본 발명은 다른 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩의 추출물을 유효성분으로 포함하는 근육 소모, 손상 또는 퇴화로 인한 근육 질환의 예방 또는 치료용 조성물을 제공한다.In another aspect, the present invention relates to a composition for preventing or treating muscle diseases caused by muscle wasting, damage or degradation, which comprises an extract of soybeans treated with a liquid obtained from immature fruit of a plant of the genus Citrus, .
본 발명은 또 다른 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩의 추출물을 유효성분으로 포함하는 대사증후군 예방 또는 치료용 조성물을 제공한다. In another aspect, the present invention provides a composition for the prevention or treatment of metabolic syndrome comprising, as an active ingredient, a liquid obtained from immature fruit of a plant belonging to the genus Citrus, or an extract of soybeans treated with the processed product.
본 발명은 또 다른 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩의 추출물을 유효성분으로 포함하는 체력 증진용 조성물을 제공한다. In another aspect, the present invention provides a composition for enhancing physical fitness comprising an extract of soybeans treated with a liquid obtained from immature fruit of a plant belonging to the genus Citrus or a processed product thereof as an active ingredient.
본 발명의 일 측면에 따른, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩의 추출물을 이용하여, 근력 강화, 근육량 증진, 대사증후군 개선, 체력 증진 등을 실현할 수 있으므로, 이를 통해 관련 소비자나 환자들의 케어 및 복지 개선에 기여할 수 있을 것이고, 해당 산업의 발전을 도모할 수 있을 것이다.According to one aspect of the present invention, by using the liquid obtained from the immature fruit of the plant of the genus Citrus, or the soybean extract treated with the processed product, it is possible to strengthen the muscle, improve the muscle mass, improve the metabolic syndrome, , Which will contribute to the improvement of care and welfare of related consumers and patients, and will help to develop the relevant industries.
도 1은 실시예 4에 따른 추출물이 농도 의존적으로 근세포 내 단백질 함량을 증진시킴을 나타낸 것이다.
도 2는 실시예 4에 따른 추출물이 S6K의 인산화를 증진시킴을 나타낸 도이다.
도 3은 mTOR 경로에 의해 단백질 생성이 증진되고 세포 성장이 향상되는 것을 모식화한 것이다.
도 4는 실시예 4에 따른 추출물이 대사증후군 관련 지표에 영향을 주는 것을 나타낸 도이다.
도 5는 실시예 4에 따른 추출물이 근육량 증가에 기여함을 나타낸 것이다.
도 6은 실시예 4에 따른 추출물이 체지방량 감소 및 골격근량 증진을 일으킴을 나타낸 것이다.
도 7은 실시예 4에 따른 추출물이 근력 기능 및 유연성 증진에 영향을 미침을 나타낸 것이다.
도 8은 실시예 4에 따른 추출물이 유연성, 심폐기능, 근력기능 및 체형에 미치는 영향을 나타낸 것이다.
도 9는 실시예 4에 따른 추출물이 허리둘레, 혈당, 중성지방, 및 총콜레스테롤 함량에 미치는 영향을 나타낸 것이다.
도 10은 실시예 4에 따른 추출물이 피로감 개선 및 컨디션 개선 등에 미치는 영향을 나타낸 것이다.FIG. 1 shows that the extract according to Example 4 improves protein content in muscle cells in a concentration-dependent manner.
Fig. 2 shows that the extract according to Example 4 promotes phosphorylation of S6K. Fig.
Figure 3 is a schematic representation of protein production enhanced and cell growth enhanced by the mTOR pathway.
4 is a graph showing that the extract according to Example 4 affects an index related to the metabolic syndrome.
Figure 5 shows that the extract according to Example 4 contributes to the increase in muscle mass.
Fig. 6 shows that the extract according to Example 4 causes decrease in body fat mass and increase in skeletal muscle mass.
Figure 7 shows that the extract according to Example 4 had an effect on the improvement of muscle function and flexibility.
Figure 8 shows the effect of the extract according to Example 4 on flexibility, cardiopulmonary function, muscle strength function and body shape.
9 shows the effect of the extract according to Example 4 on waist circumference, blood sugar, triglyceride, and total cholesterol content.
10 shows the effect of the extract according to Example 4 on improvement of fatigue and improvement of condition.
이하 본 발명에 대하여 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 명세서에서 “시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체”란, 시트러스속에 속하는 식물의 미성숙 과실에서 비롯된 모든 액체를 포함한다. 이는 시트러스속에 속하는 식물의 아직 성숙되지 않은 과실을 가공하거나 또는 가공하지 않고 과실 및 껍질 중 어느 하나 이상에서 착즙한 액을 포함한다. 또한 상기 착즙한 액을 여러 가공 및 처리 과정을 거친 후 증류하여 수득된 액, 그리고 그 수득된 액에 정제수나 이온수를 첨가하여 희석한 액 등도 포함한다.As used herein, the term " liquid obtained from immature fruit of a plant of the genus Citrus " includes all liquids derived from immature fruits of a plant belonging to the genus Citrus. This includes liquids that have been sourced from at least one of the fruit and the shell without processing or processing the unmatured fruit of the plant belonging to the genus Citrus. The liquid obtained by subjecting the juice to a variety of processing and processing steps followed by distillation, and a liquid obtained by adding purified water or ionized water to the obtained liquid.
본 명세서에서 “풋귤수(Green Mandarin water, GMW)”란, 미성숙한 감귤 및 껍질 중 어느 하나 이상에서 착즙한 액, 상기 액을 가공하거나 처리한 후 증류하여 수득된 액, 그리고 그 수득된 액에 정제수나 이온수를 첨가하여 희석한 액 등을 포함한다.The term " green mandarin water (GMW) " as used herein means a solution obtained by juicing at least one of immature citrus fruits and shells, a solution obtained by processing or treating the solution and then distilling the solution, And diluted with purified water or ionized water.
본 명세서에서 “가공물”이란 원료가 되는 물질을 통상의 방법으로 가공한 모든 물질을 의미하며, 구체적으로 원료가 되는 물질의 추출물, 가열물, 건조물, 발효물, 가수분해한 산물, 또는 증류물 등을 의미할 수 있으나, 이에 제한되는 것은 아니다.In the present specification, the term " workpiece " means any material obtained by processing a material as a raw material by a conventional method, and specifically includes an extract, a heated product, a dried product, a fermented product, a hydrolyzed product, , But is not limited thereto.
본 명세서에서 "건조 콩"은 건조를 통해 콩 내 수분을 10%(w/w)이하로 줄인 콩을 의미한다. 상기 건조는 통상의 건조방법이 모두 사용될 수 있으나, 동결건조가 바람직하다.As used herein, the term "dry bean" refers to beans that have been reduced in moisture to 10% (w / w) or less in soy bean by drying. The above drying can be carried out by any ordinary drying method, but freeze drying is preferred.
본 명세서에서 "추출물"이라 함은, 천연물로부터 그 안의 성분을 뽑아냄으로써 얻어진 물질이라면, 뽑아내는 방법이나 성분의 종류와 무관하게 모두 포함한다. 예컨대, 용매 없이 분쇄 및 착즙 중 어느 하나 이상을 통해 얻은 것, 물이나 유기 용매를 이용하여 용매에 용해되는 성분을 추출해 낸 것, 천연물의 특정 성분, 예컨대 아미노산과 같은 특정 성분만을 추출하여 얻어진 것 등을 모두 포함하는 광의의 개념이다.As used herein, the term "extract" refers to a substance obtained by extracting a component contained therein from a natural product, regardless of the method of extraction or the kind of the component. For example, those obtained through one or more of pulverization and juice without a solvent, those obtained by extracting components dissolved in a solvent using water or an organic solvent, those obtained by extracting only specific components such as amino acids, and the like And the like.
본 발명은 일 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩에서 추출한 추출물을 유효성분으로 포함하는 근력 강화 또는 근육량 증진용 조성물일 수 있다.In one aspect, the present invention may be a composition for enhancing muscle strength or muscle mass comprising, as an active ingredient, a liquid obtained from immature fruit of a plant belonging to the genus Citrus, or an extract extracted from soybeans treated with the composition.
일 구현 예에 의하면, 상기 근력 강화 또는 근육량 증진은 근세포 내 단백질량 증가에 의한 것일 수 있다.According to one embodiment, the muscle strengthening or muscle mass enhancement may be due to an increase in the amount of protein in the muscle cells.
다른 구현 예에 의하면, 상기 근력 강화 또는 근육량 증진은 근세포 내 mTOR(mammalian target of rapamycin) 경로의 활성화에 의한 것일 수 있다.According to another embodiment, the muscle strengthening or muscle mass enhancement may be due to activation of the mammalian target of rapamycin (mTOR) pathway in muscle cells.
다른 구현 예에 의하면, 상기 근력 강화 또는 근육량 증진은 근세포 내 단백질 합성 시그널인 S6K(ribosomal protein S6 kinase) 인산화 증진에 의한 것일 수 있다.According to another embodiment, the muscle strengthening or muscle mass enhancement may be due to phosphorylation of the S6K (ribosomal protein S6 kinase) protein signal in muscle cells.
본 발명은 다른 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩에서 추출한 추출물을 유효성분으로 포함하는 근육 소모, 근육 손상 또는 근육 퇴화로 인한 근육 질환의 예방 또는 치료용 조성물일 수 있다.In another aspect, the present invention relates to a method for preventing muscle wasting, muscle damage or muscle degeneration caused by muscle wasting or muscle degeneration, which comprises an extract obtained from an immature fruit of a plant belonging to the genus Citrus, Or a therapeutic composition.
일 실시예에 의하면, 근육 소모 또는 근육 퇴화는 유전적 요인, 후천적 요인, 노화 등을 원인으로 발생할 수 있으며, 근육 소모는 근육량의 점진적 손실, 근육, 특히 골격근 또는 수의근 및 심장근육의 약화 및 퇴행 등을 포함할 수 있다. 이와 관련된 질환의 예로는 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증, 악액질(cachexia) 및 근육감소증(Sacopenia) 등이 포함될 수 있다. According to one embodiment, muscle wasting or muscle degeneration may occur due to genetic factors, acquired factors, aging, etc., and muscle wasting may result in gradual loss of muscle mass, weakness and degeneration of muscles, particularly skeletal muscle or vascular and cardiac muscle . ≪ / RTI > Examples of diseases associated therewith may include atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia and sacopenia.
본 발명은 또 다른 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩에서 추출한 추출물을 유효성분으로 포함하는 대사증후군 예방 또는 치료용 조성물일 수 있다.In another aspect, the present invention may be a composition for preventing or treating metabolic syndrome comprising an extract obtained from immature fruit of a plant belonging to the genus Citrus or an extract extracted from soybeans treated with the composition.
일 구현 예에 의하면, 상기 대사증후군 예방 또는 치료는 체중감소, 복부비만 개선, 체지방 감소, 혈당감소, 및 체형개선으로 이루어진 군에서 선택되는 하나 이상에 의한 것일 수 있다.According to one embodiment, the prevention or treatment of the metabolic syndrome may be caused by one or more selected from the group consisting of weight loss, improvement of abdominal obesity, reduction of body fat, reduction of blood sugar, and improvement of body shape.
본 발명은 또 다른 측면에서, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 처리한 콩에서 추출한 추출물을 유효성분으로 포함하는 체력 증진용 조성물일 수 있다.In another aspect, the present invention may be a composition for enhancing physical fitness comprising, as an active ingredient, a liquid obtained from immature fruit of a plant belonging to the genus Citrus, or an extract extracted from soybeans treated with the processed product.
일 구현 예에 의하면, 상기 체력 증진은 심폐 기능 증진, 유연성 증진, 및 피로감 해소로 이루어진 군에서 선택되는 하나 이상일 수 있다.According to one embodiment, the physical fitness may be one or more selected from the group consisting of cardiopulmonary function enhancement, flexibility enhancement, and fatigue relief.
다른 구현 예에 의하면, 상기 액체는 미숙 과실에서 착즙한 액을 증류하여 액화시킨 액체일 수 있다. According to another embodiment, the liquid may be a liquid obtained by distilling and liquefying a liquid juice from immature fruit.
또 다른 구현 예에 의하면, 상기 액체는 미숙 과실의 효소가 불활성화된 액체일 수 있다. 일 실시태양에 따르면, 미숙 과실의 착즙액을 가열 처리 및 고압 처리 중 어느 하나 이상의 처리를 통해 미숙 과실의 효소를 불활성화시킨 것일 수 있다. 또한, 시트러스속 식물의 미숙 과실을 착즙, 가압하여 과실 내의 수분과 기타 고형분 및 향기성분을 수득하고 이후 가열 처리 또는 고압 처리하여 효소들을 불활성화할 수 있다. 본 발명의 다른 일 실시예의 풋귤수를 분리하는 단계에서, 풋귤을 착즙 처리하고 가열처리하여 효소를 불활성할 수 있다. According to another embodiment, the liquid may be a liquid in which the immature fruit enzyme is inactivated. According to one embodiment, the juice of the immature fruit may be one in which the immature fruit enzyme is inactivated through at least one of heat treatment and high-pressure treatment. In addition, immature fruits of the genus Citrus can be squeezed and pressurized to obtain water and other solid and fragrant components in the fruit, and then heat-treated or high-pressure treated to inactivate the enzymes. In another step of separating the citrus juice of one embodiment of the present invention, the citrus peel can be juiced and heat treated to inactivate the enzyme.
일 실시태양에 의하면, 상기에서 착즙액을 증류 및 액화하는 방법은 당업자에게 알려진 어떠한 방법도 사용이 가능하다. 예를 들어, 착즙액을 증류하기 위하여, 가열처리를 할 수 있다. 가열 처리는 가압 상태에서 약 100~121℃, 상압 상태에서 약 80~100℃, 또는 감압 상태에서 40~80℃에서 이루어 질 수 있다. 또한, 본 발명의 일 구현예에 따르면, 착즙액의 증류 전 또는 후 단계에서 원심 분리, 막 분리 또는 증류 분리하여 바람직하지 않은 성분을 분리 및 제거하는 단계를 더 거칠 수 있다.According to one embodiment, any of the methods known to those skilled in the art can be used to distill and liquefy the juice. For example, in order to distill the juice, a heat treatment can be performed. The heat treatment may be performed at about 100 to 121 占 폚 under pressure, about 80 to 100 占 폚 at normal pressure, or 40 to 80 占 폚 under reduced pressure. Further, according to one embodiment of the present invention, it is further possible to separate and remove undesirable components by centrifugation, membrane separation or distillation separation in the step before or after the distillation of the juice.
다른 실시태양에 따르면, 상기 가열 처리는 50 내지 150℃의 온도에서 실시하는 것일 수 있다. 온도 범위가 상기 범위 내 일 때, 상기 가열 처리에 의해 시트러스류 식물의 미숙 과실에 포함된 효소가 불활성화될 수 있다. 또한 상기 가열 처리를 통해 미생물 균총의 생육을 억제 또는 사멸시켜 오염이나 변성을 예방 할 수 있다.According to another embodiment, the heat treatment may be carried out at a temperature of 50 to 150 ° C. When the temperature range is within the above range, the enzyme contained in the immature fruit of the citrus-like plant can be inactivated by the heat treatment. In addition, it is possible to prevent contamination or denaturation by inhibiting or killing the growth of microorganism bacteria through the heat treatment.
다른 실시태양에 따르면, 상기 착즙은 압착 효과를 이용한 기어식 착즙, 프레스식 착즙, 분쇄식 착즙 및 효소 분해식 착즙으로 이루어진 군에서 선택된 하나 이상일 수 있다.According to another embodiment, the juice may be at least one selected from the group consisting of a gear type juice, a press type juice, a crushed juice and an enzymatically degraded juice using a pressing effect.
또 다른 실시태양에 따르면, 상기 액체는 유기 용매를 혼합하여 증류하는 단계를 더 거친 것일 수 있다. According to another embodiment, the liquid may be further subjected to a step of mixing and distilling an organic solvent.
또 다른 구현 예에 의하면, 상기 액체 또는 그 가공물은 리나로올(linalool), 테르피넨-4-올(terpinene-4-ol), 테르피네올(terpineol) 및 시트로넬롤(citronellol)로 이루어진 군에서 선택된 하나 이상을 포함하는 것일 수 있다.According to another embodiment, the liquid or a workpiece thereof is composed of linalool, terpinene-4-ol, terpineol and citronellol. , ≪ / RTI >
또한, 일 구현 예에 의하면, 상기 처리는 시트러스속 식물의 미숙 과실에서 얻은 액체 또는 그 가공물로 침지시키는 것일 수 있다. 일 실시태양에 따르면, 상기 침지는 5 내지 24시간 동안 실시하는 것일 수 있다. 또한 다른 실시태양에 따르면, 일정 함량의 시트러스속 식물의 미숙 과실에서 얻은 액체(또는 그 가공물)와 일정 함량의 카테킨을 함유하는 녹차추출물의 혼합물을 상기 침지에 사용할 수도 있다. 일 실시태양에 의하면 상기 함량은 0.1중량%이상, 0.5중량%이상, 1중량%이상, 2중량%이상, 3중량%이상, 4중량%이상, 5중량%이상, 6중량%이상, 8중량%이상, 10중량%이상, 12중량%이상, 또는 15중량%이상일 수 있으며 또한, 20중량%이하, 15중량%이하, 12중량%이하, 10중량%이하, 8중량%이하, 6중량%이하, 5중량%이하, 4중량%이하, 3중량%이하, 2중량%이하, 1중량%이하, 0.5중량%이하, 또는 0.1중량%이하일 수 있다. 상기 함량은 바람직하게는 2 내지 5중량%일 수 있다. 다른 실시태양에 의하면, 상기 녹차추출물 내의 카테킨 함량은 1중량%이상, 3중량%이상, 5중량%이상, 7중량%이상, 9중량%이상, 10중량%이상, 12중량%이상, 15중량%이상, 18중량%이상, 20중량%이상, 23중량%이상, 25중량%이상, 28중량%이상, 30중량%이상, 32중량%이상, 35중량%이상, 37중량%이상, 40중량%이상, 42중량%이상, 45중량%이상, 50중량%이상, 52중량%이상, 55중량%이상, 또는 60중량%이상일 수 있으며 또한, 65중량%이하, 60중량%이하, 55중량%이하, 52중량%이하, 50중량%이하, 45중량%이하, 42중량%이하, 40중량%이하, 37중량%이하, 35중량%이하, 30중량%이하, 28중량%이하, 25중량%이하, 23중량%이하, 20중량%이하, 18중량%이하, 15중량%이하, 12중량%이하, 10중량%이하, 9중량%이하, 7중량%이하, 5중량%이하, 또는 3중량%이하일 수 있다. 상기 녹차추출물 내의 카테킨 함량은 바람직하게는 35중량%일 수 있다.Further, according to an embodiment, the treatment may be to immerse with a liquid obtained from immature fruit of a citrus plant or a work thereof. According to one embodiment, the immersion may be carried out for 5 to 24 hours. According to another embodiment, a mixture of a liquid (or a workpiece) obtained from immature fruit of a certain amount of a Citrus genus plant and a green tea extract containing a certain amount of catechin may be used in the immersion. According to one embodiment, the content is 0.1 wt% or more, 0.5 wt% or more, 1 wt% or more, 2 wt% or more, 3 wt% or more, 4 wt% or more, 5 wt% or more, 6 wt% or more, Or less, 15 weight% or less, 12 weight% or less, 10 weight% or less, 8 weight% or less, 6 weight% or less, Or less, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less, 0.5 wt% or less, or 0.1 wt% or less. The above content may preferably be 2 to 5% by weight. According to another embodiment, the catechin content in the green tea extract is at least 1 wt%, at least 3 wt%, at least 5 wt%, at least 7 wt%, at least 9 wt%, at least 10 wt%, at least 12 wt% At least 20 wt%, at least 23 wt%, at least 25 wt%, at least 28 wt%, at least 30 wt%, at least 32 wt%, at least 35 wt%, at least 37 wt% %, At least 45 wt.%, At least 50 wt.%, At least 52 wt.%, At least 55 wt.%, Or at least 60 wt.%, By weight, up to 50% by weight, up to 45% by weight, up to 42% by weight, up to 40% by weight, up to 37% by weight, up to 35% by weight, up to 30% Up to 23 wt%, up to 20 wt%, up to 18 wt%, up to 15 wt%, up to 12 wt%, up to 10 wt% up to 9 wt% up to 7 wt% up to up to 5 wt% % ≪ / RTI > The catechin content in the green tea extract may preferably be 35% by weight.
다른 구현 예에 의하면, 상기 시트러스속 식물은 포멜로(Citrus maxima), 시트론(Citrus medica), 만다린(Citrus reticulate), 탱자(Citrus trifoliate), 금감(Citrus japonica), 라임(lime), 그레이프 프루츠(Citrus paradise), 레몬(Citrus limon), 사워오렌지(Citrus aurantium), 유자(Citrus junos 또는 Citrus ichangenis), 귤(Citrus unshiu), 온주 밀감(satsuma mandarin), 및 스윗오렌지(Citrus sinensis) 중 어느 하나 이상일 수 있으며, 바람직하게는 귤일 수 있다.According to another embodiment, the Citrus plant is selected from the group consisting of Citrus maxima , Citrus medica , Citrus reticulate , Citrus trifoliate , Citrus japonica , Lime, Citrus fruit, paradise , citrus limon , citrus aurantium , Citrus junos Or Citrus ichangenis , Citrus unshiu , Satsuma mandarin, and Sweet orange ( Citrus sinensis ), preferably citrus.
다른 구현 예에 의하면, 상기 미숙 과실은 성숙하지 않은 과실을 모두 이르는 말로서, 풋귤을 포함한다.According to another embodiment, the immature fruit comprises all of the unmatured fruit, and the fruit juice comprises the kumquat.
일 측면에서, 상기 라임은 오스트랄리안 핑거 라임(Citrus australasica), 오스트랄리안 라운드 라임(Citrus australis), 오스트랄리안 데저트 라임(Citrus glauca), 마운트 화이트 라임(Citrus garrawayae), 카카두 라임(Citrus gracilis), 러셀 리버 라임(Citrus inodora), 뉴지아나 와일드 라임(Citrus warburgiana), 브라운 리버 핑거 라임(Citrus wintersii) 중 어느 하나 이상일 수 있다.In one aspect, the lime Australia Raleigh eyes finger limes (Citrus australasica), Australia Raleigh, not round lime (Citrus australis), Australia Raleigh Do not Desert Lime (Citrus glauca), Mount White limes (Citrus garrawayae), Kakadu lime (Citrus gracilis , Citrus inodora , Citrus warburgiana , and Citrus wintersii ).
또 다른 구현 예에 의하면, 상기 시트러스속 식물은 만다린(Citrus reticulate), 또는 온주밀감(satsuma mandarin)일 수 있다.According to another embodiment, the Citrus plant may be mandarin ( Citrus reticulate ) or satsuma mandarin.
일 구현 예에 의하면, 상기 콩은 발아가 가능한 콩이면 제한 없이 사용될 수 있다. 예를 들어, 장류 및 두부용, 나물용, 밥밑용 또는 풋콩용 품종일 수 있다. 장류 및 두부용 품종으로는, 대풍(大豊), 호장(湖醬), 장원(壯元), 대황(大潢), 소담, 송학(松鶴), 대원(大元), 진품(眞品), 단백(蛋白), 두유(豆油), 신팔달(新八達), 태광(太光), 만리(萬里), 장수(長壽), 무한(無限), 백운(白雲), 새알, 황금(黃金) 및 장엽(長葉) 등이 있다. 나물용 품종으로는, 신화, 소원, 안평(安平), 서남(西南), 다채(多彩), 소록(小綠), 소호(小湖), 소명(疏明), 다원(多元), 풍산(豊産)나물, 익산(益山)나물, 소백(小白)나물, 광안(光安), 단엽(短葉) 및 은하(銀河) 등이 있다. 밥밑용 품종으로는, 청자(靑磁), 흑청(黑靑), 갈미(褐味), 선흑(鮮黑), 검정콩 및 일품(一品)검정콩 등이 있다. 또한, 풋콩용 품종으로는, 다올, 신록(新綠), 새을, 검정을, 석량(夕凉)풋콩, 화엄(華嚴)풋콩 및 큰을 등이 있다. 다른 측면에서, 상기 콩은 발아가 가능하고 병충해에 강한 품종인 것이 바람직하다. 그와 같은 콩으로는, 예를 들어 신화, 소원, 안평(安平), 서남(西南), 다채(多彩), 소록(小綠), 소호(小湖), 소명(疏明), 다원(多元), 풍산(豊産)나물, 익산(益山)나물, 소백(小白)나물, 광안(光安), 단엽(短葉) 및 은하(銀河) 등이 있다. 그러나 본 명세서에 있어서, 발아를 위한 콩이 상기 콩의 종류에 한정되는 것은 아니다. According to one embodiment, the soybeans can be used without limitation if they are germable beans. For example, it may be a varietal for soybean curd, tofu, herb, rice or soybean. Among the varieties for soy sauce and tofu, there are Daifeng, Hojang, Jangwon, Daehang, Sodam, Songhak, Daewon, , Protein, soybean oil, Shinpaldal, Taekwang, Manly, Jangsu, Wuhan, Baekun, Baal, ) And Chang Le (长 葉). Among the herb cultivars, there are three kinds of herbaceous varieties: Shinhwa, Suwon, Anping, Seinam, Daekwon, Sook, Soo, Daewon, Poongsan There are many herbs, Iksan herbs, small white herbs, gwangan, short leaves and galaxies. The rice varieties include celadon, black celery, brown celery, black celery, black celery, and one black culinary variety. In addition, the varieties for soybeans include daol, green, new, black, soya, soybeans, and so on. In another aspect, the soybean is preferably a variety capable of germination and resistant to pests and diseases. Such beans include, for example, myths, wishes, Anping, southwestern, colorful, small lakes, small lakes, calligraphy, ), Poongsan herbs, Iksan herbs, Sobaek herbs, Gwangan, short leaves and galaxies. However, in this specification, the soybeans for germination are not limited to the kinds of the soybean.
상기 콩에 대한 학명의 예로는, Lupinus angustifolius L., Phaseolus vulgaris, Glycine max (L.) Merr., Cyamopsis tetragonoloba (L.) Taub , Phaseolus radiatus L. var. aurea , Phaseolus vulgaris L., Canavalia gladiatia , Glycine soja Sieb . & Zucc ., Glycine ussuriensis Regel & Maack , Arachis hypogaea L., Lens culinaris Medik ., Phaseolus lunatus L., Amphicarpaea bracteata , Phaseolus multiflous Wild., Cajanus cajan (L.) Millsp . , Vicia angustifolia L. var. segetilis , Amphicarpaea edgeworthii Benth ., Rhynchosia nulubilis , Cicer arietinum L., Apios Americana, Vicia faba L., Dolichos lablab L., Ceratonia siliqua (L.) Taub ., Dipteryx odorata ( Aub L .) Willd , Phaseolus multiflorus var. albus Bailey 등을 들 수 있으나, 이에 한정되는 것은 아니다. 또한 동일한 학명을 가진 콩이라도 개량, 교잡, 색깔, 크기, 품종 등에 따라 여러 종류의 콩으로 다양하게 분류될 수 있다.Examples of scientific names for the soybean include Lupinus angustifolius L., Phaseolus vulgaris, Glycine max (L.) Merr., Cyamopsis tetragonoloba (L.) Taub , Phaseolus radiatus L. var. aurea , Phaseolus vulgaris L., Canavalia gladiatia , Glycine soja Sieb . & Zucc ., Glycine ussuriensis Regel & Maack , Arachis hypogaea L., Lens culinaris Medik . , Phaseolus lunatus L., Amphicarpaea bracteata , Phaseolus multiflous Wild., Cajanus cajan (L.) Millsp . , Vicia angustifolia L. there is. segetilis , Amphicarpaea edgeworthii Benth ., Rhynchosia nulubilis , Cicer arietinum L., Apios Americana, Vicia faba L., Dolichos lablab L., Ceratonia siliqua (L.) Taub ., Dipteryx odorata ( Aub L. ) Willd , Phaseolus There is multiflorus . albus Bailey , and the like, but are not limited thereto. Also beans with the same scientific name can be classified into various kinds of beans according to improvement, hybridization, color, size and variety.
상기 콩은 상기 처리 후 발아시킨 콩일 수 있고, 상기 콩은 신화콩일 수 있다. 일 실시태양에 의하면, 상기 발아는 12 내지 48시간 동안 실시하는 것일 수 있다. 다른 실시태양에 의하면, 상기 발아는 명발아 및 암발아 중 어느 하나 이상일 수 있다.The soybean may be the soybean germinated after the treatment, and the soybean may be the soybean. According to one embodiment, the germination may be carried out for 12 to 48 hours. According to another embodiment, the germination may be at least one of germination and cancer germination.
본 발명의 일 측면에 의하면, 상기 발아 이후에 콩을 삶는 과정이 없을 수 있다. 통상의 콩 추출물 수득 방식에서는 콩을 삶은 과정이 수반되나, 본 발명의 일 측면에서는 그러한 삶는 과정을 배제하여 영양소 파괴를 최소화한 것일 수 있다.According to an aspect of the present invention, there may be no process of boiling the soybeans after the germination. Conventional methods for obtaining soybean extract are accompanied by a process of boiling soybeans, but in one aspect of the present invention, such boiling process may be excluded to minimize nutrient destruction.
다른 구현 예에 의하면, 상기 추출은 분쇄 및 착즙 중 하나 이상을 포함하는 것일 수 있다. 예를 들어, 상기 착즙은 기어식 착즙, 프레스식 착즙, 분쇄식 착즙 및 효소 분해식 착즙으로 이루어진 군에서 선택된 하나 이상일 수 있고, 특히 맷돌로 콩을 으깬 후 천을 이용하여 착즙하는 한국 전통 방식에 의한 착즙일 수 있다.According to another embodiment, the extraction may comprise one or more of crushing and juice. For example, the juice may be at least one selected from the group consisting of a gear type juice, a press type juice, a crushed juice, and an enzymatically degraded juice, and in particular, by a Korean traditional method of crushing a bean with a millstone and then using a cloth It can be a juice.
또 다른 구현 예에 의하면, 상기 추출은 물 또는 C1 내지 C5 알코올에 의한 추출일 수 있다.According to another embodiment, said extraction may be extraction with water or a C1 to C5 alcohol.
또 다른 구현 예에 의하면, 상기 C1 내지 C5 알코올은 에탄올 일 수 있다. According to another embodiment, the C1 to C5 alcohol may be ethanol.
또 다른 구현 예에 의하면, 상기 추출은 효소에 의한 발효 또는 가수분해 과정을 더 포함하는 것일 수 있다. 상기 효소에 의한 발효 또는 가수분해는 착즙 이후에 실시하는 것이 바람직하나, 이에 제한되지는 않는다. 상기 효소는 바실러스 속 균주에서 유래한 프로테아제가 바람직하나 이에 제한되지 않는다. 상기 효소는 사카로마이세스속(Saccharomyces sp .), 바실러스속(Bacillus sp .) 락토바실러스속(Lactobacillus sp.) 및 루코노스톡속(Leuconostoc mesenteroides sp .)으로부터 선택되는 균주에서 유래한 효소일 수 있고, 바람직하게는 사카로마이세스 세레비지애(Saccharomyces cerevisiae), 락토바실러스 카세이(Lactobacillus casei), 바실러스 서브틸리스(Bacillus subtlis), 락토바실러스 불가리우스(Lactobacillus bulgarius) 및 루코노스톡 메센테로이데스(Leuconostoc mesenteroides)로부터 선택되는 균주에서 유래한 효소일 수 있다.According to another embodiment, the extraction may further include an enzymatic fermentation or hydrolysis. The fermentation or hydrolysis by the enzyme is preferably performed after the juice, but is not limited thereto. The enzyme is preferably a protease derived from a strain belonging to the genus Bacillus, but is not limited thereto. Such enzymes include Saccharomyces sp . , Bacillus sp . , Lactobacillus sp. And Leuconostoc sp. mesenteroides sp . ) May be an enzyme derived from the strain, preferably a Saccharomyces as MY process three Levy jiae (Saccharomyces cerevisiae) is selected from, Lactobacillus Kasei (Lactobacillus casei), Bacillus subtilis (Bacillus subtlis), Lactobacillus non-vitreous ( Lactobacillus bulgarius ) and Leuconostoc mesenteroides ( Leuconostoc mesenteroides ). < / RTI >
또 다른 구현 예에 의하면, 상기 발효 또는 가수분해는 20도씨 이상, 25도씨 이상, 30 도씨 이상, 40 도씨 이상, 50 도씨 이상, 55 도씨 이상, 60 도씨 이상, 또는 65 도씨 이상에서 실시하는 것일 수 있다. 또한, 67 도씨 이하, 65 도씨 이하, 60 도씨 이하, 55 도씨 이하, 50 도씨 이하, 45 도씨 이하, 40 도씨 이하, 30 도씨 이하, 또는 25 도씨 이하에서 실시하는 것일 수 있다. 또 다른 구현 예에 의하면, 상기 발효 또는 가수분해 시간은 5시간 이상, 7 시간 이상, 9 시간 이상, 10 시간 이상, 12 시간 이상, 14 시간 이상, 15 시간 이상, 16 시간 이상, 18 시간 이상, 20 시간 이상, 또는 24 시간 이상일 수 있다. 또한, 25 시간 이하, 24 시간 이하, 20 시간 이하, 18 시간 이하, 16 시간 이하, 14 시간 이하, 12 시간 이하, 10 시간 이하, 9 시간 이하, 8 시간 이하, 또는 7 시간 이하일 수 있다. According to another embodiment, the fermentation or hydrolysis may be performed at a temperature above 20 degrees Celsius, above 25 degrees Celsius, above 30 degrees Celsius, above 40 degrees Celsius, above 50 degrees Celsius, above 55 degrees Celsius, above 60 degrees Celsius, It may be carried out by more than Mr. Do. In addition, it shall be conducted at 67 degrees or less, 65 degrees or less, 60 degrees or less, 55 degrees or less, 50 degrees or less, 45 degrees or less, 40 degrees or less, 30 degrees or less, Lt; / RTI > In another embodiment, the fermentation or hydrolysis time is at least 5 hours, at least 7 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 18 hours, 20 hours or more, or 24 hours or more. It may be 25 hours or less, 24 hours or less, 20 hours or less, 18 hours or less, 16 hours or less, 14 hours or less, 12 hours or less, 10 hours or less, 9 hours or less, 8 hours or less or 7 hours or less.
또 다른 구현 예에 의하면, 상기 조성물은 대두배아를 열수로 추출한 추출물과 L-카르니틴의 혼합물, 로이신, 페닐알라닌, 및 메티오닌으로 이루어진 군에서 선택된 하나 이상을 더 포함하는 것일 수 있다. 일 실시예에 의하면, 상기 대두배아를 열수로 추출한 추출물(“대두배아 열수추출물”)과 L-카르니틴의 혼합물은 통상 “APIC”로 시중에 알려진 혼합 조성물일 수 있으며, 식품의약품안전처에 개별인정형 건강기능식품 원료로 인정된 것일 수 있다. 상기 대두배아 열수추출물과 L-카르니틴의 혼합 비율은 중량 기준으로 4:3일 수 있다. 일 실시태양에 의하면, 상기 대두배아 열수추출물은, 대두의 배아를 분리한 후 열수를 이용하여 추출하고(90~100도씨, 30~60분), 여과 후 수지에 흡착시킨 뒤 60% 에탄올로 용리하고, 용리액을 원심분리 후 농축(1 내지 2시간)하여 시클로덱스트린을 일정량 첨가하여 90℃이상에서 살균한 뒤, 건조시킨 것일 수 있다. 다른 실시태양에 의하면 상기 대두배아 열수추출물과 L-카르니틴의 혼합 비율은 중량 기준으로 m:n일 수 있고, 여기서 m과 n은 각각 1 내지 5일 수 있다. According to another embodiment, the composition may further comprise at least one selected from the group consisting of a mixture of L-carnitine and an extract obtained by extracting a soybean embryo with hot water, leucine, phenylalanine, and methionine. According to one embodiment, a mixture of the hot-water extract of the soybean embryo ("soybean embryo hot-water extract") and L-carnitine can be a commonly known mixed composition commonly known as "APIC" It may be recognized as an orthopedic health functional food raw material. The mixing ratio of the soybean embryo hydrothermal extract to L-carnitine may be 4: 3 by weight. According to one embodiment, the hot-water extract of soybean embryo is extracted with hot water (90 to 100 degrees C for 30 to 60 minutes) after separating the embryo of soybeans, adsorbed to the resin after filtration, and then washed with 60% ethanol After eluting the eluate, it is concentrated (1 to 2 hours), added with a certain amount of cyclodextrin, sterilized at 90 ° C or higher, and then dried. According to another embodiment, the mixing ratio of the soybean embryo hydrothermal extract to L-carnitine may be m: n by weight, wherein m and n may each be 1 to 5.
일 구현 예에 의하면, 상기 추출물은 추출물 총 중량 대비 수용성 펩타이드 및 아미노산의 함량이 5 중량% 이상, 10중량% 이상, 15중량% 이상, 20중량% 이상, 25중량% 이상, 30중량% 이상, 35중량% 이상, 40중량% 이상, 45중량% 이상, 48중량% 이상, 50중량% 이상, 55중량% 이상, 60중량% 이상, 65중량% 이상일 수 있다. 또한, 70중량% 이하, 65중량% 이하, 60 중량% 이하, 55중량 % 이하, 50중량% 이하, 48중량% 이하, 45중량% 이하, 40중량% 이하, 35중량% 이하, 30중량% 이하, 25중량% 이하, 20중량% 이하, 15중량% 이하, 또는 10중량% 이하일 수 있다. 바람직하게는 상기 함량이 40 내지 60 중량%일 수 있다. According to one embodiment, the extract comprises at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30% At least 35% by weight, at least 40% by weight, at least 45% by weight, at least 48% by weight, at least 50% by weight, at least 55% by weight, at least 60% by weight and at least 65% by weight. Or less, 70 wt% or less, 65 wt% or less, 60 wt% or less, 55 wt% or less, 50 wt% or less, 48 wt% or less, 45 wt% or less, 40 wt% or less, 35 wt% Or less, 25 weight% or less, 20 weight% or less, 15 weight% or less, or 10 weight% or less. Preferably, the content may be 40 to 60% by weight.
또 다른 구현 예에 의하면, 상기 추출물은 하기 특성 중 하나 이상을 가지는 것인, 조성물일 수 있다.According to another embodiment, the extract may be a composition having one or more of the following characteristics.
a) 총 유리 아미노산의 함량이 상기 추출물 전체 중량을 기준으로 0.4 내지 2.5 중량%;a) the content of total free amino acids is from 0.4 to 2.5% by weight, based on the total weight of the extract;
b) BCAA의 함량이 상기 추출물 전체 중량을 기준으로 0.1 내지 1.5 중량%;b) 0.1 to 1.5% by weight, based on the total weight of the extract, of BCAA;
c) 류신(leucine)의 함량이 상기 추출물 전체 중량을 기준으로 0.03 내지 0.1 중량%;c) the content of leucine is 0.03 to 0.1% by weight based on the total weight of the extract;
d) 발린(valine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.5 중량%;d) 0.01 to 0.5% by weight, based on the total weight of the extract, of valine;
e) 아이소류신(Isoleucine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.7 중량%;e) the content of isoleucine is from 0.01 to 0.7% by weight, based on the total weight of the extract;
f) GABA의 함량이 상기 추출물 전체 중량을 기준으로 0.03 내지 0.15 중량%;f) 0.03 to 0.15% by weight, based on the total weight of the extract, of GABA;
g) 글루탐산(Glutamic acid)의 함량이 상기 추출물 전체 중량을 기준으로 0.05 내지 0.4 중량%;g) 0.05 to 0.4% by weight, based on the total weight of the extract, of glutamic acid;
h) 페닐알라닌(Phenylalanine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.5 중량%; 및h) 0.01 to 0.5% by weight, based on the total weight of the extract, of phenylalanine; And
i) 알라닌(Alanine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.5 중량%.i) 0.01 to 0.5% by weight, based on the total weight of the extract, of alanine.
일 구현 예에 의하면, 상기 총 아미노산의 함량이 상기 추출물에 대하여 0.4 내지 2.5 중량%일 수 있다. 구체적으로, 상기 추출물 총 중량 대비 총 아미노산의 함량은 0.4중량%이상, 0.8중량%이상, 1.0중량%이상, 1.2중량%이상, 1.4중량%이상, 1.6중량%이상, 1.64중량%이상, 1.8중량%이상, 2.0중량%이상, 2.2중량%이상, 또는 2.4중량%이상일 수 있으며, 또한, 2.5중량%이하, 2.2중량%이하, 2.0중량%이하, 1.8중량%이하, 1.64중량%이하, 1.6중량%이하, 1.4중량%이하, 1.2중량%이하, 1.0중량%이하, 0.8중량%이하, 또는 0.6중량%이하 일 수 있다.According to one embodiment, the total amino acid content may be 0.4 to 2.5% by weight based on the extract. Specifically, the total amino acid content relative to the total weight of the extract is 0.4 wt% or more, 0.8 wt% or more, 1.0 wt% or more, 1.2 wt% or more, 1.4 wt% or more, 1.6 wt% or more, 1.64 wt% or more, 1.8 wt% , Not more than 2.0 wt%, not more than 2.0 wt%, not more than 1.8 wt%, not more than 1.64 wt%, 1.6 wt% Or less, 1.4 wt% or less, 1.2 wt% or less, 1.0 wt% or less, 0.8 wt% or less, or 0.6 wt% or less.
또한, 상기 총 아미노산 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물(“타사 콩 추출물” 또는 “타사 콩 펩타이드 추출물”)의 총 아미노산 함량에 비해 3배 이상일 수 있다. 구체적으로, 3배 이상, 4배 이상, 5배 이상, 6배 이상, 7배 이상, 7.5배 이상, 8배 이상, 8.2배 이상, 8.5배 이상, 9배 이상, 또는 10배 이상일 수 있다.In addition, the total amino acid content is determined by comparing the total amino acid content of the germinated soybean extract ("Third Party Soybean Extract" or "Third Party Soy Peptide Extract") treated with distilled water (or immersion) and boiled in place of the liquid obtained from immature fruit of the genus Citrus It can be more than three times the total amino acid content. Specifically, it may be 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 7.5 times or more, 8 times or more, 8.2 times or more, 8.5 times or more, 9 times or more or 10 times or more.
본 발명의 또 다른 측면에서, 상기 추출물 총 중량 대비 BCAA의 함량이 0.1 내지 1.5 중량%일 수 있다. 류신(leucine), 아이소류신(isoleucine) 및 발린(valine)은 브랜치드-체인 아미노산(Branched-chain amino acid, BCAA)로 불리기도 한다. 일 실시태양에 의하면, 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체를 처리함으로써 발아 콩의 영양성분 중 아미노산의 함량을 높임과 동시에 BCAA의 함량을 높일 수 있다. 구체적으로 상기 BCAA의 함량은 상기 추출물 총 중량 대비 0.1중량% 이상, 0.3중량% 이상, 0.5중량% 이상, 0.8중량% 이상, 1.0중량% 이상, 1.2중량% 이상, 또는 1.4중량% 이상일 수 있으며, 또한, 1.5중량% 이하, 1.3중량% 이하, 1.1중량% 이하, 1.0중량% 이하, 0.8중량% 이하, 0.6중량% 이하, 0.5중량% 이하, 0.3중량% 이하, 또는 0.2중량% 이하일 수 있다. In another aspect of the present invention, the content of BCAA may be 0.1 to 1.5% by weight based on the total weight of the extract. Leucine, isoleucine and valine are also referred to as branched-chain amino acids (BCAA). According to one embodiment, by treating a liquid obtained from immature fruit of a plant belonging to the genus Citrus, it is possible to increase the content of amino acids and increase the content of BCAA in the nutritional components of germinated beans. Specifically, the content of BCAA may be at least 0.1 wt%, at least 0.3 wt%, at least 0.5 wt%, at least 0.8 wt%, at least 1.0 wt%, at least 1.2 wt%, or at least 1.4 wt% based on the total weight of the extract, And may be 1.5 wt% or less, 1.3 wt% or less, 1.1 wt% or less, 1.0 wt% or less, 0.8 wt% or less, 0.6 wt% or less, 0.5 wt% or less, 0.3 wt% or less, or 0.2 wt% or less.
또한, 상기 BCAA의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 BCAA 함량에 비해 5배 이상일 수 있다. 구체적으로, 5배 이상, 7배 이상, 9배 이상, 10배 이상, 12배 이상, 15배 이상, 17배 이상, 19배 이상, 20배 이상, 22배 이상, 22.9배 이상, 24배 이상, 25배 이상, 또는 27배 이상일 수 있다.In addition, the content of BCAA may be 5 times or more as much as that of germinated soybean extract obtained by treating (or dipping) with distilled water instead of liquid obtained from immature fruit of Citrus plant. More specifically, at least 5 times, at least 7 times, at least 9 times, at least 10 times, at least 12 times, at least 15 times, at least 17 times, at least 19 times, at least 20 times, at least 22 times, at least 22.9 times, at least 24 times , 25 times or more, or 27 times or more.
본 발명은 또 다른 측면에서, 상기 추출물 총 중량 대비 류신(leucine)의 함량이 0.03 내지 0.1 중량%일 수 있다. 구체적으로 상기 류신의 함량은 0.03중량% 이상, 0.05중량% 이상, 0.06중량% 이상, 0.07중량% 이상, 0.072중량% 이상, 0.08중량% 이상, 또는 0.09중량% 이상일 수 있으며, 또한, 0.1중량% 이하, 0.09중량% 이하, 0.08중량% 이하, 0.072중량% 이하, 0.07중량% 이하, 0.06중량% 이하, 0.05중량% 이하, 또는 0.04중량% 이하일 수 있다. In another aspect of the present invention, the content of leucine with respect to the total weight of the extract may be 0.03 to 0.1% by weight. Specifically, the content of leucine may be 0.03 wt% or more, 0.05 wt% or more, 0.06 wt% or more, 0.07 wt% or more, 0.072 wt% or more, 0.08 wt% or more, or 0.09 wt% 0.07 wt% or less, 0.08 wt% or less, 0.072 wt% or less, 0.07 wt% or less, 0.06 wt% or less, 0.05 wt% or less, or 0.04 wt% or less.
또한, 상기 류신(leucine)의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 류신 함량에 비해 5 배 이상일 수 있다. 구체적으로, 5배 이상, 7배 이상, 9 배 이상, 10 배 이상, 12 배 이상, 13 배 이상, 15 배 이상, 18 배 이상, 또는 20 배 이상일 수 있다.The leucine content may be 5 times higher than the leucine content of the germinated soybean extract obtained by treating (or dipping) with distilled water instead of the liquid obtained from the immature fruit of a plant belonging to the genus Citrus. Specifically, it may be 5 times or more, 7 times or more, 9 times or more, 10 times or more, 12 times or more, 13 times or more, 15 times or more, 18 times or more or 20 times or more.
본 발명의 또 다른 측면에서, 상기 추출물 총 중량에 대하여 발린(valine)의 함량이 0.01 내지 0.5 중량%인, 발아 콩을 제공한다. 구체적으로, 상기 발린의 함량은 0.01중량% 이상, 0.03중량% 이상, 0.05중량% 이상, 0.07중량% 이상, 0.09중량% 이상, 0.1중량% 이상, 0.121중량% 이상, 0.15중량% 이상, 0.2중량% 이상, 0.3중량% 이상, 또는 0.4중량% 이상일 수 있으며, 또한, 0.5중량% 이하, 0.4중량% 이하, 0.3중량% 이하, 0.2중량% 이하, 0.15중량% 이하, 0.121중량% 이하, 0.1중량% 이하, 0.09중량% 이하, 0.07중량% 이하, 0.05중량% 이하, 0.03중량% 이하, 또는 0.02중량% 이하일 수 있다. In another aspect of the present invention, there is provided a germinated bean having a valine content of 0.01 to 0.5 wt% based on the total weight of the extract. Specifically, the content of valine is 0.01 wt% or more, 0.03 wt% or more, 0.05 wt% or more, 0.07 wt% or more, 0.09 wt% or more, 0.1 wt% or more, 0.121 wt% or more, 0.15 wt% or more, 0.2 wt% %, 0.4 wt% or less, 0.3 wt% or less, 0.2 wt% or less, 0.15 wt% or less, 0.121 wt% or less, 0.1 wt% or less, %, 0.09 wt% or less, 0.07 wt% or less, 0.05 wt% or less, 0.03 wt% or less, or 0.02 wt% or less.
또한, 상기 발아 콩의 발린(valine)의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 발린 함량에 비해 5배 이상일 수 있다. 구체적으로, 5배 이상, 7배 이상, 9배 이상, 10배 이상, 12배 이상, 15배 이상, 17배 이상, 17.3배 이상, 18배 이상, 또는 20배 이상일 수 있다.In addition, the valine content of the germinated beans can be 5 times or more than the valine content of the germinated soybean extract that has been treated (or soaked) with distilled water and boiled instead of the liquid obtained from the immature fruit of a plant of the genus Citrus have. Specifically, it may be 5 times or more, 7 times or more, 9 times or more, 10 times or more, 12 times or more, 15 times or more, 17 times or more, 17.3 times or more, 18 times or more or 20 times or more.
본 발명의 또 다른 측면에서, 상기 추출물 총 중량에 대하여 아이소류신(Isoleucine)의 함량이 0.01 내지 0.7 중량%인, 조성물을 제공한다. 구체적으로, 상기 류신의 함량은 0.01중량% 이상, 0.03중량% 이상, 0.05중량% 이상, 0.08중량% 이상, 0.1중량% 이상, 0.2중량% 이상, 0.3중량% 이상, 0.31중량% 이상, 0.4중량% 이상, 0.5중량% 이상, 또는 0.6중량% 이상일 수 있으며, 또한, 0.7중량% 이하, 0.6중량% 이하, 0.5중량% 이하, 0.4중량% 이하, 0.31중량% 이하, 0.29중량% 이하, 0.2중량% 이하, 0.1중량% 이하, 0.08중량% 이하, 0.05중량% 이하, 0.03중량% 이하, 또는 0.01중량% 이하일 수 있다. In another aspect of the present invention, there is provided a composition wherein the content of isoleucine is 0.01 to 0.7% by weight, based on the total weight of the extract. Specifically, the leucine content may be 0.01 wt% or more, 0.03 wt% or more, 0.05 wt% or more, 0.08 wt% or more, 0.1 wt% or more, 0.2 wt% or more, 0.3 wt% or more, 0.31 wt% or more, 0.5% or less, 0.4% or less, 0.31% or less, 0.29% or less, 0.2% or less by weight, Or less, 0.1 wt% or less, 0.08 wt% or less, 0.05 wt% or less, 0.03 wt% or less, or 0.01 wt% or less.
또한, 상기 아이소류신(Isoleucine)의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 아이소류신 함량에 비해 10 배 이상일 수 있다. 구체적으로, 10배 이상, 15배 이상, 18 배 이상, 20 배 이상, 23 배 이상, 25 배 이상, 28 배 이상, 30 배 이상, 32 배 이상, 34 배 이상, 34.4 배 이상, 35 배 이상, 40배 이상 또는 45 배 이상일 수 있다.In addition, the content of isoleucine may be 10 times or more as much as that of germinated soybean extract obtained by treating (or dipping) with distilled water instead of liquid obtained from immature fruit of a plant of the genus Citrus (Citrus) . More specifically, at least 10 times, at least 15 times, at least 18 times, at least 20 times, at least 23 times, at least 25 times, at least 28 times, at least 30 times, at least 32 times, at least 34 times, at least 34.4 times, at least 35 times , 40 times or more, or 45 times or more.
본 발명의 또 다른 측면에서, 상기 추출물 총 중량에 대하여 GABA의 함량이 0.03 내지 0.15 중량%인, 조성물을 제공한다. 구체적으로 상기 GABA의 함량은 0.03중량% 이상, 0.04중량% 이상, 0.05중량% 이상, 0.054중량% 이상, 0.08중량% 이상, 0.1중량% 이상, 0.12중량% 이상, 또는 0.14중량% 이상일 수 있으며, 또한, 0.15중량% 이하, 0.14중량% 이하, 0.12중량% 이하, 0.1중량% 이하, 0.08중량% 이하, 0.054중량% 이하, 0.05중량% 이하, 또는 0.04중량% 이하일 수 있다. In another aspect of the invention, there is provided a composition wherein the content of GABA is 0.03 to 0.15% by weight, based on the total weight of the extract. Specifically, the content of the GABA may be 0.03 wt% or more, 0.04 wt% or more, 0.05 wt% or more, 0.054 wt% or more, 0.08 wt% or more, 0.1 wt% or more, 0.12 wt% or more, or 0.14 wt% 0.15 wt% or less, 0.12 wt% or less, 0.1 wt% or less, 0.08 wt% or less, 0.054 wt% or less, 0.05 wt% or less, or 0.04 wt% or less.
또한, 상기 추출물의 GABA의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지) 하고 삶는 과정을 거친 발아 콩 추출물의 GABA 함량에 비해 2.5 배 이상일 수 있다. 구체적으로, 2.5배 이상, 2.8배 이상, 3.0 배 이상, 3.5 배 이상, 3.8 배 이상, 4.0 배 이상, 4.2 배 이상, 4.5 배 이상, 4.7 배 이상, 5.0 배 이상, 5.1 배 이상, 5.5 배 이상 또는 6.0 배 이상일 수 있다.In addition, the content of GABA in the extract may be 2.5 times or more than that of the germinated soybean extract obtained by treating (or dipping) with distilled water instead of the liquid obtained from immature fruit of a plant of the genus Citrus. Specifically, it is 2.5 times or more, 2.8 times, 3.0 times, 3.5 times, 3.8 times, 4.0 times, 4.2 times, 4.5 times, 4.7 times, 5.0 times, 5.1 times, 5.5 times Or 6.0 times or more.
본 발명의 또 다른 측면에서, 상기 추출물의 총 중량 대비 글루탐산의 함량이 0.05 내지 0.4 중량%인, 조성물을 제공한다. 구체적으로 상기 글루탐산의 함량은 0.05중량% 이상, 0.07중량% 이상, 0.09중량% 이상, 0.1중량% 이상, 0.135중량% 이상, 0.2중량% 이상, 또는 0.3중량% 이상일 수 있으며, 또한, 0.4중량% 이하, 0.3중량% 이하, 0.2중량% 이하, 0.15중량% 이하, 0.135중량% 이하, 0.1중량% 이하, 0.09중량% 이하, 또는 0.07중량% 이하일 수 있다. In another aspect of the present invention, there is provided a composition wherein the content of glutamic acid relative to the total weight of the extract is 0.05 to 0.4 wt%. More specifically, the content of glutamic acid may be 0.05 wt% or more, 0.07 wt% or more, 0.09 wt% or more, 0.1 wt% or more, 0.135 wt% or more, 0.2 wt% or more, or 0.3 wt% Or less, 0.3 wt% or less, 0.2 wt% or less, 0.15 wt% or less, 0.135 wt% or less, 0.1 wt% or less, 0.09 wt% or less, or 0.07 wt% or less.
또한, 상기 추출물의 글루탐산의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 글루탐산 함량에 비해 5 배 이상일 수 있다. 구체적으로, 5배 이상, 5.6배 이상, 5.8 배 이상, 6 배 이상, 6.5 배 이상, 7 배 이상, 7.2 배 이상, 7.5 배 이상, 7.7 배 이상, 또는 8 배 이상일 수 있다.In addition, the content of glutamic acid in the extract may be 5 times or more than the amount of glutamic acid in germinated soybean extract treated with distilled water (or dipped) and boiled in place of the liquid obtained from immature fruit of a plant of the genus Citrus. Specifically, it may be 5 times or more, 5.6 times or more, 5.8 times or more, 6 times or more, 6.5 times or more, 7 times or more, 7.2 times or more, 7.5 times or more, 7.7 times or more or 8 times or more.
본 발명의 또 다른 측면에서, 상기 추출물 총 중량 대비 페닐알라닌의 함량이 0.01 내지 0.5 중량%인, 조성물을 제공한다. 구체적으로 상기 페닐알라닌의 함량은 0.01중량% 이상, 0.05중량% 이상, 0.08중량% 이상, 0.1중량% 이상, 0.13중량% 이상, 0.15중량% 이상, 0.18중량% 이상, 0.2중량% 이상, 0.23중량% 이상, 0.236중량% 이상, 0.3중량% 이상, 0.4중량% 이상, 또는 0.45중량% 이상일 수 있으며, 또한, 0.5중량% 이하, 0.45중량% 이하, 0.4중량% 이하, 0.3중량% 이하, 0.236중량% 이하, 0.23중량% 이하, 0.2중량% 이하, 0.18중량% 이하, 0.15중량% 이하, 0.13중량% 이하, 0.1중량% 이하, 0.08중량% 이하, 또는 0.05중량% 이하일 수 있다. In another aspect of the present invention, there is provided a composition wherein the content of phenylalanine is 0.01 to 0.5% by weight based on the total weight of the extract. Specifically, the content of the phenylalanine is 0.01% by weight, 0.05% by weight, 0.08% by weight, 0.1% by weight, 0.13% by weight, 0.15% by weight, 0.18% by weight, 0.2% by weight or more, 0.23% , Not more than 0.25 wt%, not more than 0.45 wt%, not more than 0.4 wt%, not more than 0.3 wt%, not more than 0.236 wt%, and more preferably not less than 0.236 wt%, not less than 0.3 wt%, not less than 0.4 wt% Or less, 0.23 wt% or less, 0.2 wt% or less, 0.18 wt% or less, 0.15 wt% or less, 0.13 wt% or less, 0.1 wt% or less, 0.08 wt% or less, or 0.05 wt% or less.
또한, 상기 추출물의 페닐알라닌의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 페닐알라닌 함량에 비해 10 배 이상일 수 있다. 구체적으로, 10배 이상, 12배 이상, 15 배 이상, 17배 이상, 20 배 이상, 23 배 이상, 26 배 이상, 26.2 배 이상, 28 배 이상, 30배 이상, 32배 이상 또는 35 배 이상일 수 있다.In addition, the content of phenylalanine in the extract may be 10 times or more as much as the content of phenylalanine in germinated soybean extract, which has been treated (or soaked) with distilled water and boiled, instead of the liquid obtained from immature fruit of a plant belonging to the genus Citrus. More specifically, it may be at least 10 times, at least 12 times, at least 15 times, at least 17 times, at least 20 times, at least 23 times, at least 26 times, at least 26.2 times, at least 28 times, at least 30 times, at least 32 times, .
본 발명의 또 다른 측면에서, 상기 추출물 총 중량 대비 알라닌의 함량이 0.01 내지 0.5 중량%인, 조성물을 제공한다. 구체적으로, 상기 알라닌의 함량은 0.01중량% 이상, 0.03중량% 이상, 0.05중량% 이상, 0.07중량% 이상, 0.09중량% 이상, 0.1중량% 이상, 0.114중량% 이상, 0.15중량% 이상, 0.2중량% 이상, 0.25중량% 이상, 0.3중량% 이상, 또는 0.4중량% 이상일 수 있으며, 또한, 0.5중량% 이하, 0.4중량% 이하, 0.3중량% 이하, 0.25중량% 이하, 0.2중량% 이하, 0.5중량% 이하, 0.114중량% 이하, 0.1중량% 이하, 0.09중량% 이하, 0.07중량% 이하, 0.05중량% 이하, 또는 0.03중량% 이하일 수 있다.In another aspect of the present invention, there is provided a composition wherein the content of alanine relative to the total weight of the extract is 0.01 to 0.5% by weight. Specifically, the content of alanine is 0.01 wt% or more, 0.03 wt% or more, 0.05 wt% or more, 0.07 wt% or more, 0.09 wt% or more, 0.1 wt% or more, 0.114 wt% or more, 0.15 wt% or more, %, 0.4 wt% or less, 0.3 wt% or less, 0.25 wt% or less, 0.2 wt% or less, 0.5 wt% or less, Or less, 0.114 wt% or less, 0.1 wt% or less, 0.09 wt% or less, 0.07 wt% or less, 0.05 wt% or less, or 0.03 wt% or less.
또한, 상기 추출물의 알라닌의 함량은 시트러스(Citrus)속 식물의 미숙 과실에서 얻은 액체 대신 증류수로 처리(또는 침지)하고 삶는 과정을 거친 발아 콩 추출물의 알라닌 함량에 비해 3배 이상일 수 있다. 구체적으로, 3배 이상, 4배 이상, 5 배 이상, 6배 이상, 7배 이상, 8 배 이상, 9 배 이상, 10 배 이상, 12 배 이상, 또는 15배 이상일 수 있다.In addition, the alanine content of the extract may be three times or more as much as the alanine content of the germinated soybean extract that has been treated (or dipped) with distilled water instead of the liquid obtained from the immature fruit of a plant of the genus Citrus. Specifically, it may be 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, 9 times or more, 10 times or more, 12 times or more or 15 times or more.
본 발명의 일 측면에 의한, 시트러스(Citrus)속 식물의 미숙 과실을 착즙, 가열, 증류하여 얻은 액체 또는 그 가공물로 침지한 콩을 발아시킨 후 그 발아 콩을 삶지 않고 전통 분쇄 및 착즙 방식(맷돌에 의한 분쇄 후, 천을 이용하여 착즙하는 방식)으로 착즙하며 바실러스 속(특히 바실러스 서브틸리스) 유래 효소(프로테아제)로 발효 또는 가수분해시킨 후 농축 및 살균을 거친 다음, 근세포에 미치는 영향을 알아보았다. 상기 추출물은 발아 콩에서 착즙한 액, 즉 발아두즙으로부터 유래한 것이고, 상기한 바와 같이 아미노산 및 펩타이드가 다량 함유되어 있다. 그러한 펩타이드(이를 “발아두즙 펩타이드”라 한다)를 함유하는 상기 추출물은 근세포내 단백질의 양을 농도의존적으로 현저히 증진시키고, 단백질 합성 경로인 mTOR-S6K 경로와 관련하여 S6K의 인산화를 촉진시키는 것을 확인하였다(도 1 내지 2 참조). 이를 통해, 상기 발아두즙 펩타이드를 함유하는 추출물을 근력 강화 또는 근육량 증진에 사용할 수 있음을 명백히 규명하였고, 이를 통해 본 명세서를 근육 소모, 근육 손상 또는 근육 퇴화로 인한 근육 질환의 예방 또는 치료에 활용할 수 있음을 확인하였다.In accordance with one aspect of the present invention, there is provided a method for producing a fermented beverage, which comprises germinating soybeans immersed in a liquid obtained by juicing, heating and distilling immature fruit of a plant belonging to the genus Citrus, And then subjected to fermentation or hydrolysis with an enzyme derived from Bacillus genus (especially Bacillus subtilis) (protease), followed by concentration and sterilization, and then the effect on muscle cells was examined . The extract is derived from a liquid juice from germinated soybeans, that is, germination juice, and contains a large amount of amino acids and peptides as described above. The extracts containing such peptides (referred to herein as "germinated juice peptides") significantly enhance the amount of protein in muscle cells in a concentration-dependent manner and promote the phosphorylation of S6K in association with the mTOR-S6K pathway for protein synthesis (See Figs. 1 to 2). Thus, it has been clarified that the extract containing the germicidal peptide can be used for the enhancement of muscle strength or the improvement of muscle mass, thereby enabling the present specification to be used for preventing or treating muscle diseases caused by muscle wasting, muscle damage or muscle regeneration Respectively.
또한, 상기 발아두즙 펩타이드를 함유하는 추출물을 피험자에게 경구투여한 결과, 체중감소, 복부비만 개선, 체지방 감소, 혈당 감소, 체형 개선 등의 효과가 나타나 대사증후군의 예방, 치료 및 개선에도 본 명세서를 활용할 수 있음을 확인하였고, 체력 증진 등의 효과도 나타내어 본 명세서를 그러한 용도로도 활용할 수 있음을 확인하였다(도 4 내지 10 참조).In addition, oral administration of the extract containing the germicidal peptide to a subject resulted in effects such as weight loss, improvement in abdominal obesity, decrease in body fat, decrease in blood glucose, and improvement in body shape, thereby preventing, treating and improving the metabolic syndrome. (See FIGS. 4 to 10), and that the present invention can also be utilized for such purposes by showing the effect of improving physical fitness and the like.
일 실시태양에 따르면, 상기 조성물 내의 상기 추출물의 함량은 조성물 총 중량을 기준으로 0.01 중량% 내지 70 중량%일 수 있다. 또한 상기 함량은 0.01중량% 이상, 0.05중량% 이상, 0.1중량% 이상, 0.5중량% 이상, 1중량% 이상, 5중량% 이상, 10중량% 이상, 15중량% 이상, 20중량% 이상, 25중량% 이상, 30중량% 이상, 35중량% 이상, 40중량% 이상, 45중량% 이상, 50중량% 이상, 55중량% 이상, 60중량% 이상, 또는 65중량% 이상일 수 있다. 또는 상기 함량은 70중량% 이하, 65중량% 이하, 60중량% 이하, 55중량% 이하, 50중량% 이하, 45중량% 이하, 40중량% 이하, 35중량% 이하, 30중량% 이하, 25중량% 이하, 20중량% 이하, 15중량% 이하, 10중량% 이하, 5중량% 이하, 1중량% 이하, 0.5중량% 이하, 0.1중량% 이하, 또는 0.05중량% 이하일 수 있다.According to one embodiment, the content of the extract in the composition may be from 0.01% to 70% by weight, based on the total weight of the composition. The content may be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, at least 0.5 wt%, at least 1 wt%, at least 5 wt%, at least 10 wt%, at least 15 wt% At least 30 wt%, at least 35 wt%, at least 40 wt%, at least 45 wt%, at least 50 wt%, at least 55 wt%, at least 60 wt%, or at least 65 wt%. Or the content is 70 wt% or less, 65 wt% or less, 60 wt% or less, 55 wt% or less, 50 wt% or less, 45 wt% or less, 40 wt% or less, 35 wt% or less, 30 wt% Up to 20 weight percent, up to 15 weight percent, up to 10 weight percent, up to 5 weight percent, up to 1 weight percent, up to 0.5 weight percent, up to 0.1 weight percent, or up to 0.05 weight percent.
다른 실시태양에 따르면, 상기 추출물의 투여량은 100 mg/kg/일 내지 800 mg/kg/일 일 수 있다. 또한, 상기 투여량은 100mg/kg/일 이상, 150mg/kg/일 이상, 200mg/kg/일 이상, 250mg/kg/일 이상, 300mg/kg/일 이상, 350mg/kg/일 이상, 400mg/kg/일 이상, 450mg/kg/일 이상, 500mg/kg/일 이상, 600mg/kg/일 이상, 700mg/kg/일 이상, 또는 750mg/kg/일 이상일 수 있다. 또는, 상기 투여량은 800mg/kg/일 이하, 750mg/kg/일 이하, 700mg/kg/일 이하, 650mg/kg/일 이하, 600mg/kg/일 이하, 550mg/kg/일 이하, 500mg/kg/일 이하, 500mg/kg/일 이하, 450mg/kg/일 이하, 400mg/kg/일 이하, 350mg/kg/일 이하, 300mg/kg/일 이하, 250mg/kg/일 이하, 200mg/kg/일 이하, 또는 150mg/kg/일 이하일 수 있다. According to another embodiment, the dose of the extract may be 100 mg / kg / day to 800 mg / kg / day. The dosage may be at least 100 mg / kg / day, at least 150 mg / kg / day, at least 200 mg / kg / day, at least 250 mg / kg / day, at least 300 mg / kg / day, at least 350 mg / kg / day, at least 450 mg / kg / day, at least 500 mg / kg / day, at least 600 mg / kg / day, at least 700 mg / kg / day, or at least 750 mg / kg / day. Alternatively, the dose may be in the range of 800 mg / kg / day, 750 mg / kg / day, 700 mg / kg / day, 650 mg / kg / day, 600 mg / kg / day, 550 mg / kg or less, 500 mg / kg / day, 450 mg / kg / day, 400 mg / kg / day, 350 mg / kg / day, 300 mg / kg / day, 250 mg / / Day, or 150 mg / kg / day or less.
또 다른 실시태양에 따르면, 상기 조성물은 액상일 수 있다. 기존의 단백질 보충제제나 근력 증진 제품의 경우 분말 제품이어서, 이를 섭취하기 위해서는 다시 정제수, 우유, 주스 등과 같은 액상 제품에 혼합하여 섭취할 수 밖에 없는 불편함이 있었다. 액상으로 유통시킬 경우 성분의 안정성이 유지되지 않아 제품의 품질이 변하고 효과가 상실되기 때문이었다. 또한 액상제품과 혼합하여 섭취하는 과정에서 화학반응, 응집, 성분 변성 등이 일어날 수도 있고, 흡수 저해 등이 일어나기도 하였다. 본 발명의 일 실시예에 의하면, 상기 제형은 액상으로 제형화하여 보관 및 유통이 가능하므로 섭취 전에 혼합 과정 등을 별도로 거칠 필요가 없어 기존의 제품들 보다 섭취하기가 훨씬 간편하며, 상기와 같은 문제가 발생할 우려가 없는 이점이 있다. According to another embodiment, the composition may be in a liquid phase. In the case of conventional protein supplements and muscle strengthening products, they are powder products, and in order to ingest them, they have to be mixed with liquid products such as purified water, milk, juice, and the like. The reason for this is that the stability of the ingredients is not maintained and the quality of the product is changed and the effect is lost. In addition, chemical reactions, aggregation, and component denaturation may occur during mixing with the liquid product and absorption inhibition may occur. According to one embodiment of the present invention, since the formulation can be stored and distributed in a liquid form, it is not necessary to separately perform a mixing process before ingestion, so that it is much easier to ingest than existing products, There is an advantage that there is no possibility of occurrence.
또 다른 실시태양에 따르면, 상기 조성물은 약학적 조성물 또는 식품 조성물 일 수 있다.According to another embodiment, the composition may be a pharmaceutical composition or a food composition.
본 발명의 일측면에서, 상기 약학 조성물은 일 측면에서 약학 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 일 측면에서 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 덱스트린, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있다. In one aspect of the invention, the pharmaceutical composition may further comprise, in one aspect, suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In one aspect, carriers, excipients and diluents that may be included in the composition include lactose, dextrose, dextrin, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한, 상기 약학적 조성물은 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition may be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like, oral preparation, suppository and sterilized injection solution according to a conventional method .
제제화할 경우에는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제 등을 통상 사용한다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함될 수 있다. 이러한 고형 제제에는 상기 유효성분 외에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴을 포함할 수 있다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 포함될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 있으며, 흔히 사용되는 단순 희석제인 물, 액상 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 라우린지, 카카오지, 글리세로제라틴 등이 사용될 수 있다.In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient is usually used. Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, and the like. Such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, and gelatin in addition to the active ingredient. In addition to simple excipients, lubricants such as magnesium stearate talc may also be included. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppositories include witepsol, macrogol, tween 61, laurin, cacao butter, glycerogelatin and the like.
상기 식품 조성물은 액상 또는 고체 상태의 제형일 수 있고, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능식품류, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용될 수 있다. 각 제형의 식품 조성물은 유효성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The food composition may be in a liquid or solid form and may be in the form of, for example, various foods, beverages, gums, tea, vitamin complexes, health functional foods, health supplement foods, Can be used. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
본 명세서에 개시된 유효성분 외에 함유할 수 있는 액체 성분에는 특별한 제한점이 없으며, 통상의 음료와 같이 여러가지 향미제 또는 천연 탄수화물 등을 추가성분으로 포함할 수 있다. 상기 천연 탄수화물의 예로는 모노사카라이드, 포도당, 과당 등의 디사카라이드, 말토스, 슈크로스 등의 폴리사카라이드, 덱스트린, 시클로덱스트린 등의 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올 등이 있다. 상기의 향미제로는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(예를 들어 사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 명세서에 개시된 조성물 100ml 당 일반적으로 약 1 내지 20g, 일측면에서 약 5 내지 12g일 수 있다.There are no particular limitations on the liquid components that can be contained in addition to the active ingredients disclosed in this specification, and may include various flavoring agents or natural carbohydrates such as ordinary beverages as additional ingredients. Examples of the natural carbohydrate include common saccharides such as disaccharides such as monosaccharide, glucose and fructose, polysaccharides such as maltose and sucrose, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol . The above flavoring agents can be advantageously used as natural flavorings (tau martin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (for example, saccharin, aspartame etc.) The ratio of the natural carbohydrate may be generally about 1 to 20 g per 100 ml of the composition disclosed herein, and about 5 to 12 g per side.
상기 식품 조성물은 일 측면에서 여러가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그 염, 알긴산 및 그 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 다른 측면에서 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 상기 성분들은 독립적으로 또는 조합하여 사용될 수 있다. 상기 첨가제의 비율은 다양할 수 있으나, 본 명세서에 개시된 조성물 100 중량부 당 0.001 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In one aspect, the food composition may contain flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies such as cheese and chocolate, pectic acid and its salts, alginic acid and its salts , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. On the other hand, flesh for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination. The proportion of the additive may vary, but is generally selected in the range of from 0.001 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
[실시예 1] 풋귤수의 제조[Example 1] Preparation of foot citrus water
풋귤(온주밀감의 미숙상태)을 ㈜주영인터네셔널에서 구입하였다. 상기 구입한 풋귤에서 이물을 제거하기 위해 정제수로 세척하고, 과실의 성숙을 막기 위해 저온(5-7℃)에서 보관하였다. 상기 풋귤을 스크류식 착즙기를 사용하여 착즙하고 가압처리를 하였다. 풋귤의 효소를 불활성화 시키기 위해 70℃에서 가열 처리를 하였다. 이후 18~30메쉬 사이즈 망을 통과시켜 잔여 고형분을 제거하였다. 상기 고형분을 제거한 착즙액을 감압농축기에 투입하고 30mmHg, 100-121℃에서 가열처리를 하여 증류한 액을 모아 풋귤수를 수득하였다. Pusan (immature state of Wonju citrus) was purchased from Ju Yeong International. The purchased mutton was washed with purified water to remove foreign matter and stored at low temperature (5-7 ° C) to prevent fruit maturation. The dried persimmon was juiced using a screw-type juicer and pressurized. Heat treatment was carried out at 70 캜 to inactivate the enzyme of the citrus fruit. The remaining solid was then removed by passing through a mesh of 18 to 30 mesh size. The juice solution from which the solid content was removed was placed in a vacuum concentrator and subjected to heat treatment at 30 mmHg at 100-121 ° C to obtain a distilled water.
[실시예 2] 풋귤수의 성분 분석[Example 2] Analysis of composition of foot water
실시예 1의 풋귤수의 성분을 확인하기 위해 GC 분석을 진행하였다. GC analysis was carried out to identify the components of the foot water of Example 1.
분석 방법 : GC/MS 분석, HS-SPME(Headspace Solid-Phase Microextraction)Analysis method: GC / MS analysis, HS-SPME (Headspace Solid-Phase Microextraction)
분석 조건 : Column: DB-WAX/ Oven 조건: 50 (5min) ~240℃/3℃/min (80min)Analysis conditions: Column: DB-WAX / Oven Condition: 50 (5min) ~ 240C / 3C / min (80min)
Inj.Temp.: 230/ Splitless/threshold:16.5Inj .: 230 / Splitless / threshold: 16.5
풋귤수의 성분을 분석한 결과를 표 1에 기재하였다.The results of analyzing the components of the foot water are shown in Table 1.
[실시예 3] 발아콩의 제조[Example 3] Production of germinated beans
-침지 전처리: 신화콩 200g을 증류수 500ml로 세척하였다(2회 반복). 세척한 콩을 침지수 600ml를 사용하여 25도씨 인큐베이터에서 4~20시간 침지하였는데, 다른 실시예에서는 15시간 동안 침지시켰다. 이때 침지수로 실시예 1에 따른 풋귤수와 증류수를 사용한 경우를 비교하기 위해, 침지수로 실시예 1에 따른 풋귤수 600ml에 침지한 군과 침지수로 증류수 600ml를 사용한 군을 구분하여 침지 전처리를 시행하였다. 또한, 다른 실시예로서 2 내지 5중량%의 상기 풋귤수와 35중량%의 카테킨을 함유하는 녹차추출물의 혼합물을 침지수로 사용하였다.- Immersion pretreatment: 200 g of myth bean was washed with 500 ml of distilled water (repeated twice). The washed soybeans were soaked in a 25 ° C incubator using 600 ml of immersion for 4 to 20 hours, in other embodiments immersed for 15 hours. In order to compare the case of using the seawater according to Example 1 and the distilled water according to Example 1, the sediment index was divided into the group immersed in 600 ml of the water of the citric acid according to Example 1 and the group using 600 ml of distilled water, Respectively. As another example, a mixture of green tea extract containing 2 to 5% by weight of the citrus fruit juice and 35% by weight of catechin was used as a needle index.
-발아 재배기: 침지가 종료된 콩의 침지액을 버리고 증류수 500ml로 세척한 뒤(2회 반복) 콩 재배기(청시루, 신창INC)의 발아트레이에 콩을 투입하고 균일한 두께로 도포하였다. 발아수로서 증류수를 각각 2000ml을 투입하고 10~100시간 동안 25도씨의 인큐베이터에 콩 재배기를 놓아두고 발아시켰다. 콩 재배기를 통해 20분 마다 1분간 발아수를 콩의 표면에 분사하였다. - Germination cultivator: The soybean immersion solution after the immersion was discarded, washed with 500 ml of distilled water (repeated twice), and the soybean was put into the germination tray of the soybean growing machine (Chungsilu, Shinchang, INC) and applied with a uniform thickness. 2000 ml of distilled water was added as germination water, and the soybean grower was placed in an incubator of 25 ° C for 10 to 100 hours for germination. The seeds were sprayed on the surface of soybeans for 1 minute every 20 minutes through a soybean grower.
-발아 중 발아액 교체: 발아시간이 24시간 이상일 경우 매 24시간 마다 1회씩 발아수를 교체하였다. 즉, 24시간 경과된 발아액은 폐기하고 발아액 2000ml를 새로 투입하면서, 상기 발아재배 방법을 반복하였다. - Replacement of germination during germination: If the germination time is more than 24 hours, the number of germination is changed once every 24 hours. That is, the germination solution that passed 24 hours was discarded, and the germination cultivation method was repeated while 2000 ml of germination solution was newly added.
-발아 종료: 발아가 종료된 발아액은 모두 폐기하였다. 발아 중인 콩의 상태를 확인하고 콩을 증류수 2000ml로 1회 세척한 후, 2000ml의 증류수에 콩을 침지하여 60도씨 워터배스에 1시간 동안 중탕하여 콩의 효소를 실활시켰다.- End of germination: All of the germination solution which germinated was discarded. After confirming the status of germinating beans, soybean was washed once with 2000 ml of distilled water, then soybean was immersed in 2000 ml of distilled water, and soybean enzyme was inactivated by bathing in a 60 ° C water bath for 1 hour.
[실시예 4] 발아두즙 펩타이드 함유 추출물의 제조[Example 4] Preparation of extract containing germinated juice peptide
200kg의 신화콩을 상기 실시예 3에 따라 발아시켰고, 1일 동안 발아시킨 발아콩을 전통 착즙 공정인 두즙 공정(콩을 삶지 않고 맷돌로 콩을 으깬 후 천을 이용하여 손 또는 기구로 즙을 짜내는 공정)을 통해 착즙한 후 두즙을 얻었다. 그 후 효소(바실러스 속 특히 바실러스 서브틸리스 유래의 프로테아제)로 가수분해(50도씨, 16시간)시키고 농축 및 살균 과정을 거쳐 수용성 펩타이드와 아미노산의 총 함량이 50% 이하인, 발아두즙 펩타이드가 함유된 추출물 250kg을 얻었다. 상기 추출물에 대하여 아래 표 2와 같이 성분 분석을 실시하였고 분석 결과는 아래 표 3과 같다.200 kg of myth bean was germinated in accordance with the above Example 3. The germinated soybeans germinated for 1 day were processed in a conventional juicing process (the beans were not boiled, the beans were milled in a millstone, and the cloth was squeezed with a hand or an instrument After the juice was obtained through the process, the juice was obtained. Then, it is hydrolyzed (50 ° C., 16 hours) with an enzyme (protease derived from Bacillus genus, in particular Bacillus subtilis), concentrated and sterilized to obtain a germicidal peptide having a total content of water-soluble peptide and amino acid of 50% 250 kg of the extracted extract was obtained. The components of the extract were analyzed as shown in Table 2 below. The results of the analysis are shown in Table 3 below.
상기 표를 통해 알 수 있듯, 침지수로 풋귤수를 사용한 경우 증류수를 사용한 경우보다 총 유리아미노산 함량이 8.2배 높았고, BCAA(branched chain amino acid) 함량은 약 23배 가량 높아졌음을 알 수 있었다. 이와 같이 발아두즙에서 유래한 펩타이드(“발아두즙 펩타이드”)를 다량 함유한 추출물을 하기 실험예에서 사용하였다.As can be seen from the above table, the total free amino acid content was 8.2 times higher and BCAA (branched chain amino acid) content about 23 times higher than that of distilled water. Thus, an extract containing a large amount of peptides derived from germinated juice (" germinated juice peptides ") was used in the following experimental examples.
[실험예 1] 단백질 농도 측정[Experimental Example 1] Measurement of protein concentration
C2C12 근세포(American Type Culture Collection, Manassa, VA, USA)를 6-웰 플레이트에 각 웰당 1 x 105 세포의 밀도로 투여하고 10% FBS (fetal bovine serum)를 함유하는 DMEM 배지에 배양하였고, 이후 2% HS (horse serum)를 함유하는 DMEM 배지에서 1주일간 분화시켰다. 분화가 완료되면 무혈청 배지로 교체하여 다른 단백질 및 성장인자에 의한 영향을 배제하였고, 이후 상기 실시예 4에 따라 얻은 발아두즙 펩타이드 함유 추출물, 타사 콩 추출물(풋귤수를 사용하지 않은 콩을 삶은 뒤 믹서기로 갈아서 얻은 추출물)을 농도별로 처리한 후 24시간 뒤 Radioimmunoprecipitation assay buffer (RIPA buffer)를 이용하여 근세포에서 단백질을 추출하였고 BCA 에세이(Bicinchoninic acid assay)로 근세포내 단백질량을 측정하였다. 즉, BCA soultion 1 : BCA solution 2 = 50:1로 섞은 200ml에 각 샘플 1ml에 섞어 30분간 인큐베이션(incubation)하고, 562nm에서 흡광도를 측정하여 단백질을 정량하였다. C2C12 muscle cells (American Type Culture Collection, Manassa, VA, USA) administration of 6-well plates in density of 1 x 10 5 per well for each cell, and were cultured in DMEM medium containing 10% FBS (fetal bovine serum) , after 2% HS (horse serum) for 1 week. After completion of the differentiation, the medium was replaced with serum-free medium to eliminate the influence of other proteins and growth factors. Then, the extract containing the germinated juice peptide obtained according to Example 4, the soybean extract After 24 hours, proteins were extracted from muscle cells using radioimmunoprecipitation assay buffer (RIPA buffer) and the amount of protein in muscle cells was measured by BCA assay. That is, 1 ml of each sample was mixed with 200 ml of BCA soultion 1:
그 결과, 도 1과 같이, 상기 발아두즙 펩타이드 함유 추출물의 농도가 증가할 수록 단백질 농도가 증가함을 확인하였다(도 1에서 X축의 숫자는 ppm을 나타낸다). 또한, 풋귤수를 사용하지 않은 타사 콩 펩타이드를 함유한 추출물에 비하여, 실시예 4에 따라 얻은 발아두즙 펩타이드 함유 추출물이 근세포에서 보다 현저하게 단백질 농도를 증가시킴을 알 수 있었다. As a result, as shown in FIG. 1, it was confirmed that the protein concentration increases as the concentration of the germinated peptide-containing extract increases (the number of the X-axis in FIG. 1 indicates ppm). In addition, it was found that the extract containing the germinated juice peptide obtained according to Example 4 significantly increased the protein concentration in the muscle cells, as compared with the extract containing the non-soybean soybean peptides without the use of foot water.
[실험예 2] S60K의 인산화 확인[Experimental Example 2] Phosphorylation confirmation of S60K
상기 실험예와 같이 분화시킨 C2C12 근세포에 무혈청 배지(serum-free media) 처리 후 각각의 근세포에 류신(leucine), 실시예 4에 따라 얻은 발아두즙 펩타이드 함유 추출물, 타사 콩 추출물(풋귤수를 사용하지 않은 콩에서 얻은 펩타이드를 함유하는 추출물을 30분간 처리하였다. 류신(Leucine) 농도는 발아두즙 펩타이드 함유 추출물 1,000 / 5,000ppm에 함유된 류신 농도와 같도록 처리하였다(예를 들어, 상기 발아두즙 펩타이드 함유 추출물 1,000 / 5,000ppm에 류신이 4% 함유된 경우, 류신을 각각 40, 200 ppm 처리).After the serum-free media treatment of the differentiated C2C12 myocytes as described in the above Experimental Example, leucine was added to each muscle cell, the extract containing the germicide peptide obtained according to Example 4, and a soybean extract The leucine concentration was treated to be equal to the leucine concentration contained in the 1,000 / 5,000 ppm extract of the germinated juice peptide (e. G., The germicidal peptide < RTI ID = 0.0 > Containing 4% leucine at 1,000 / 5,000 ppm, leucine is treated at 40, 200 ppm respectively).
그 후, mTOR signal과 직결된 S60K의 인산화를 확인하였다. 즉, RIPA buffer 200ml로 세포를 녹여 4도씨, 12,000rpm에서 15분간 원심분리 후 상청액을 수거하였다. 이후 상기와 같이 BCA 에세이를 이용하여 단백질 정량 후 40mg씩 웨스턴 블럿(western blot)을 실시하였다. 그 결과는 도 2와 같았다. 즉, 발아두즙 펩타이드 함유 추출물(도면에서 “발아두즙콩”)을 처리할 경우 농도 의존적으로 S6K가 인산화됨을 관찰할 수 있었고, 이를 통해 mTOR의 경로가 활성화됨을 알 수 있었으며, 동일 용량의 타사콩 추출물(도면에서 “타사콩”)에서는 S6K 인산화 정도가 상기 발아두즙 펩타이드 함유 추출물 및 류신(leucine)에 비해 미미하여 mTOR 경로의 활성화가 미약함을 알 수 있었다. 상기 발아두즙 펩타이드 함유 추출물의 경우 동일 함유량의 류신에 비해 S6K 인산화를 증가시켰다. 이러한 점을 통해, 상기 발아두즙 펩타이드 함유 추출물에 의해 근세포 성장이 증진될 것임을 알 수 있다. 도 2에서 1은 아무 것도 처리하지 않은 세포군이고, 2는 류신 40ppm을 처리한 군이며, 3은 류신을 200ppm 처리한 군이고, 4 내지 6은 타사 콩 추출물을 각각 100ppm, 1000ppm, 5000ppm 사용한 군이고, 7 내지 9는 상기 발아두즙 펩타이드 함유 추출물을 각각 100ppm, 1000ppm, 5000ppm 사용한 군이며, p-S6K는 인산화된 S6K를 나타낸다. Thereafter, the phosphorylation of S60K directly linked to the mTOR signal was confirmed. That is, the cells were dissolved with 200 ml of RIPA buffer, centrifuged at 4,000 rpm for 15 minutes at 12,000 rpm, and the supernatant was collected. After quantification of the protein using the BCA assay as described above, 40 mg of western blot was performed. The results are shown in Fig. In other words, S6K phosphorylation was observed in a concentration-dependent manner when the extract containing germinated juice peptides ("germinated soybeans" in the figure) was treated. As a result, it was found that the mTOR pathway was activated, (In the figure, " other soybean "), the degree of phosphorylation of S6K was insignificant compared to the extract containing germinated juice peptide and leucine, indicating that mTOR pathway activation was weak. The extracts containing germinated squalene peptides increased S6K phosphorylation compared to the same contents of leucine. From this point, it can be seen that the germinal juice peptide-containing extract will enhance muscle cell growth. In FIG. 2, 1 indicates the group treated with nothing, 2 indicates the group treated with leucine at 40 ppm, 3 indicates the group treated with leucine at 200 ppm, and 4 through 6 indicates the groups using 100 ppm, 1000 ppm, , 7 to 9 are the groups in which the extracts containing the germicidal peptide were used at 100 ppm, 1000 ppm and 5000 ppm, respectively, and p-S6K represents phosphorylated S6K.
[실험예 3] 피험자를 대상으로 한 테스트 및 설문조사[Experimental Example 3] Tests and questionnaires for subjects
피험자를 대상으로 상기 실시예 4의 발아두즙 펩타이드 함유 추출물의 효과를 확인하였다.The effect of the germicidal peptide-containing extract of Example 4 was confirmed on the subjects.
구체적으로, 우선 만 45세 내지 65세 피험자들을 모집하여 SMI(Skeletal muscle mass index)가 6.75(kg/m2) 미만으로 근감소(Sarcopenia) 직전 상태이고, BMI(체질량지수, body mass index)가 24.0 ~ 29.9 kg/m2이며, WHR(Waist Hip Ratio, 허리 둘레/엉덩이 둘레 수치)가 0.85 이상인 피험자 10인을 선정하였다. SMI는 appendicular lean mass/height2 수치(appendicular lean mass는 제지방을 나타냄. height2은 키의 제곱을 나타냄)를 이용하여 평가하였고, 상기 SMI, WHR 및 BMI는 체성분 분석기(인바디사, 한국)를 이용하여 측정하였다.Specifically, the subjects were recruited from the age of 45 to 65 years, and the SMI (skeletal muscle mass index) was less than 6.75 (kg / m 2 ) and the BMI (body mass index) 24.0 ~ 29.9 are kg / m 2, WHR (waist hip Ratio, waist / hip size) is 0.85 or higher were selected as subjects for 10. SMI is an appendicular lean mass / height 2 The values of SMI, WHR, and BMI were measured using a body composition analyzer (Invadia, Korea). The values were measured using the numerical value (appendicular lean mass represents fat, height 2 represents the square of the key).
선정된 피험자 10인을 대상으로 상기 발아두즙 펩타이드 함유 추출물이 포함된 조성물(조성물 내 상기 추출물의 함량은 0.5% 또는 200mg)을 경구투여하였고(8주간, 1일 2회, 회당 조성물 40ml 또는 40g), 그 결과 도 4와 같이 허리둘레, BMI, 체지방량, 체지방률, 및 WHR이 현저하게 감소함을 확인하였다(“Baseline”은 상기 발아두즙 펩타이드 함유 추출물이 포함된 조성물을 투여하기 전에 측정한 수치들을 나타낸 것이다). 10 selected subjects were orally administered the composition containing the germicidal peptide-containing extract (0.5% or 200 mg of the extract in the composition) (8-week, twice daily, 40 ml or 40 g of the composition per day) As a result, it was confirmed that the waist circumference, BMI, body fat mass, percent body fat, and WHR were significantly decreased as shown in Fig. 4 ("Baseline" indicates the values measured before the administration of the composition containing the germicidal peptide- will be).
또한, 좌우 다리 근육량을 측정한 결과를 도 5으로 나타내었다. 상기 발아두즙 펩타이드 함유 추출물을 8주간 경구투여한 결과, 하체 근육량과 SMI가 현저하게 증가하였음을 확인할 수 있었다.(여기서의 SMI (%)는 골격근 매스/바디 매스 X 100 을 의미하고, LM은 lean mass 즉 제지방량을 의미한다)Fig. 5 shows the results of measurement of muscle mass of the left and right legs. As a result of oral administration of the germicidal peptide-containing extract for 8 weeks, it was confirmed that the lower body muscle mass and SMI were significantly increased (SMI (%) means skeletal muscle mass /
또한, 체구성 변화를 확인한 결과를 각각 도 6로 나타내었다. 상기 발아두즙 펩타이드 함유 추출물을 투여한 결과, 체중, 체지방량은 감소하였고 근육량과 제지방량은 증가하였으며, 체중 대비 골격근량도 증가함을 확인하였다.Fig. 6 shows the result of confirming the sieve structure change. As a result of administration of the germicidal peptide - containing extract, the body weight and fat mass were decreased, the muscle mass and fat mass were increased, and the skeletal muscle amount relative to body weight was also increased.
상기 발아두즙 펩타이드 함유 추출물을 투여하기 전후의 운동능력 및 유연성을 비교하고 설문조사를 실시한 결과, 근력 기능, 심폐 기능 및 유연성이 현저하게 변화함을 확인하였고, 이를 통해 체력 증진 효과가 나타났음을 알 수 있었다(도 7 및 도 8, 도면상 상대악력은 악력(kg)/체중(kg) X 100 이다). 도 7에서 컬업테스트는 윗몸일으키기를 뜻한다. As a result of comparing the exercise capacity and flexibility before and after administration of the germicidal peptide-containing extract, the results of the questionnaire showed that the muscle function, cardiopulmonary function and flexibility were remarkably changed, (Fig. 7 and Fig. 8, where the relative grip force is the gripping force (kg) / body weight (kg) X 100). In FIG. 7, the test for the pull-up refers to a sit-up.
한편, 대사증후군 관련 지표를 확인한 결과 도 9과 같이 나타나, 상기 발아두즙 펩타이드 함유 추출물이 대사증후군 관련 지표의 개선에 도움이 되고, 나아가 대사증후군의 예방, 개선 및 치료에 효과가 있는 것으로 확인되었다.Meanwhile, as shown in FIG. 9, the extracts containing the germinated juice peptides were found to be effective in the improvement of the metabolic syndrome-related index, and furthermore, it was found to be effective in the prevention, improvement and treatment of the metabolic syndrome.
피험자의 체감 효과를 설문조사로서 확인한 결과는 도 10과 같다. 즉, 피험자들은 상기 발아두즙 펩타이드 함유 추출물 투여에 의한 체중감소, 체지방감소, 근력 개선을 인지하였고, 피로감 개선, 컨디션 개선 등을 만족스런 효과로 들었다.The result of checking the effect of the subject on the questionnaire is shown in Fig. That is, the subjects perceived weight loss, body fat reduction, and muscle strength improvement by administration of the germicidal peptide-containing extract, and the fatigue improvement and the condition improvement were satisfactory.
본 발명의 일 측면에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Formulation examples of compositions according to one aspect of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the invention.
[제형예 1] 간편 제형(RTD: ready to drink) [Formulation Example 1] RTD (ready to drink)
대두배아를 열수로 추출한 추출물과 L-카르니틴을 4:3의 중량 비율로 섞은 혼합물(APIC), 로이신, 페닐알라닌, 메티오닌을 각각 700mg, 600mg, 80mg, 40mg(또한, 각각 1.75%, 1.5%, 0.2%, 0.1%의 중량비율)으로 준비하고, 실시예 4의 추출물 적당량과 다른 부가적인 원료들을 혼합하여 액상 형태로 제조하였고, 곧바로 섭취할 수 있는 형태(RTD: ready to drink)로 구현하였다. 600 mg, 80 mg, and 40 mg (respectively, 1.75%, 1.5%, 0.2%) of the mixture of the extract of the soybean embryo extracted with hot water and the mixture of L-carnitine in a weight ratio of 4: 3 (APIC), leucine, phenylalanine and methionine %, 0.1% by weight). The extract was prepared in the form of a liquid by mixing the appropriate amount of the extract of Example 4 and other additional raw materials, and was made into a ready-to-drink (RTD) form.
[제형예 2] 연질캅셀제[Formulation Example 2] Soft capsule
실시예 4의 추출물 200mg, L-카르니틴 80~140mg, 대두유 180mg, 팜유 2mg, 식물성 경화유 8mg, 황납 4mg 및 레시틴 6mg을 혼합하고, 통상의 방법에 따라 1캡슐에 충진하여 연질캅셀제를 제조하였다.A soft capsule was prepared by mixing 200 mg of the extract of Example 4, 80 to 140 mg of L-carnitine, 180 mg of soybean oil, 2 mg of palm oil, 8 mg of vegetable hydrogenated oil, 4 mg of yellow radish and 6 mg of lecithin and filling them into 1 capsule according to a conventional method.
[제형예 3] 정제[Formulation Example 3] Tablets
실시예 4의 추출물 200mg, 갈락토올리고당 200mg, 유당 60mg 및 맥아당 140mg을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester)를 6mg을 첨가하여 타정기로 타정하여 정제를 제조하였다.200 mg of the extract of Example 4, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose were mixed and granulated using a fluidized bed drier, followed by addition of 6 mg of sugar ester and tabletting by tableting.
[제형예 4]과립제[Formulation Example 4]
실시예 4의 추출물 200mg, 무수결정 포도당 250mg 및 전분 550mg을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하여 과립제를 제조하였다.200 mg of the extract of Example 4, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed and granulated into granules using a fluidized bed granulator, followed by filling the granules.
[제형예 5] 건강식품[Formulation Example 5] Health food
하기 표 4에 기재된 조성에 따라 통상적인 방법으로 건강 식품을 제조하였다.Healthy foods were prepared in a conventional manner according to the compositions shown in Table 4 below.
상기 비타민 및 무기질 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 예로 혼합 조성하였으나, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the vitamin and the mineral mixture is relatively mixed with the ingredient suitable for health food, the compounding ratio of the vitamin and the mineral mixture may be arbitrarily varied. The ingredients may be mixed according to a conventional method for producing health food, Can be used for the production of health food compositions.
[제형예 6] 건강음료[Formulation Example 6] Health drinks
상기 표 5와 같이 총 부피 900㎖가 되도록 잔량의 정제수를 첨가하여 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2리터 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 건강음료를 제조하였다.As shown in Table 5, a remaining amount of purified water was added to a total volume of 900 ml, and the above components were mixed according to a conventional health drink manufacturing method. After stirring for about 1 hour at 85 캜, the solution was filtered Sterilized 2 liter container, sealed sterilized, and stored in a refrigerator to prepare a health drink.
이상, 본 발명내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (25)
a) 총 유리 아미노산의 함량이 상기 추출물 전체 중량을 기준으로 0.4 내지 2.5 중량%;
b) BCAA의 함량이 상기 추출물 전체 중량을 기준으로 0.1 내지 1.5 중량%;
c) 류신(leucine)의 함량이 상기 추출물 전체 중량을 기준으로 0.03 내지 0.1 중량%;
d) 발린(valine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.5 중량%;
e) 아이소류신(Isoleucine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.7 중량%;
f) GABA의 함량이 상기 추출물 전체 중량을 기준으로 0.03 내지 0.15 중량%;
g) 글루탐산(Glutamic acid)의 함량이 상기 추출물 전체 중량을 기준으로 0.05 내지 0.4 중량%;
h) 페닐알라닌(Phenylalanine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.5 중량%; 및
i) 알라닌(Alanine)의 함량이 상기 추출물 전체 중량을 기준으로 0.01 내지 0.5 중량%.10. The composition according to any one of claims 1 to 9, wherein the extract has one or more of the following characteristics.
a) the content of total free amino acids is from 0.4 to 2.5% by weight, based on the total weight of the extract;
b) 0.1 to 1.5% by weight, based on the total weight of the extract, of BCAA;
c) the content of leucine is 0.03 to 0.1% by weight based on the total weight of the extract;
d) 0.01 to 0.5% by weight, based on the total weight of the extract, of valine;
e) the content of isoleucine is from 0.01 to 0.7% by weight, based on the total weight of the extract;
f) 0.03 to 0.15% by weight, based on the total weight of the extract, of GABA;
g) 0.05 to 0.4% by weight, based on the total weight of the extract, of glutamic acid;
h) 0.01 to 0.5% by weight, based on the total weight of the extract, of phenylalanine; And
i) 0.01 to 0.5% by weight, based on the total weight of the extract, of alanine.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160126419A KR20180036167A (en) | 2016-09-30 | 2016-09-30 | Composition for increasing muscular strength and muscle mass comprising bean juice-peptides derived from germinated bean treated with green mandarin water |
PCT/KR2017/010451 WO2018062777A1 (en) | 2016-09-30 | 2017-09-22 | Muscular strength and muscle mass improving composition comprising soybean juice peptide derived from germinated soybean treated with unripened tangerine water |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160126419A KR20180036167A (en) | 2016-09-30 | 2016-09-30 | Composition for increasing muscular strength and muscle mass comprising bean juice-peptides derived from germinated bean treated with green mandarin water |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180036167A true KR20180036167A (en) | 2018-04-09 |
Family
ID=61763538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160126419A KR20180036167A (en) | 2016-09-30 | 2016-09-30 | Composition for increasing muscular strength and muscle mass comprising bean juice-peptides derived from germinated bean treated with green mandarin water |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20180036167A (en) |
WO (1) | WO2018062777A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190142058A (en) * | 2018-06-15 | 2019-12-26 | (주)마린바이오프로세스 | Composition for prevention and treatment of muscular disorders or improvement of muscular functions comprising functional fermented material using oyster |
KR20200078093A (en) | 2018-12-21 | 2020-07-01 | (주)에이앤바이오 | The composition for preventing patella luxation and muscle strengthening for companion animals |
KR20210070682A (en) * | 2019-12-05 | 2021-06-15 | 대봉엘에스 주식회사 | Antibacterial and antifungal composition comprising vegetation water from Citrus Unshiu |
WO2022220458A1 (en) * | 2021-04-16 | 2022-10-20 | 한국생명공학연구원 | Composition including aurantii fructus immaturus extract as active ingredient for prevention or treatment of male climacteric symptom |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100360306B1 (en) * | 1999-09-09 | 2002-11-18 | 조 건 식 | Culture method and culturing solution of soybean sprout |
KR20050116082A (en) * | 2004-06-04 | 2005-12-09 | 함정희 | Preparation method of fermented soybean using extract of fruit and vegetable |
EP1723856A1 (en) * | 2005-05-18 | 2006-11-22 | Cargill, Inc. | Citrus fruit fibers in processed meat |
NZ601611A (en) * | 2010-01-04 | 2015-07-31 | Burcon Nutrascience Mb Corp | Stabilization of citrus fruit beverages comprising soy protein |
CN102630945B (en) * | 2012-03-29 | 2015-09-30 | 桐庐上品汇食品有限公司 | A kind of health composition |
KR102200014B1 (en) * | 2013-05-06 | 2021-01-08 | (주)아모레퍼시픽 | Composition for preventing and treating climacteric symptoms comprising extract of bean containing coumestrol |
-
2016
- 2016-09-30 KR KR1020160126419A patent/KR20180036167A/en not_active Application Discontinuation
-
2017
- 2017-09-22 WO PCT/KR2017/010451 patent/WO2018062777A1/en active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190142058A (en) * | 2018-06-15 | 2019-12-26 | (주)마린바이오프로세스 | Composition for prevention and treatment of muscular disorders or improvement of muscular functions comprising functional fermented material using oyster |
KR20200078093A (en) | 2018-12-21 | 2020-07-01 | (주)에이앤바이오 | The composition for preventing patella luxation and muscle strengthening for companion animals |
KR20210070682A (en) * | 2019-12-05 | 2021-06-15 | 대봉엘에스 주식회사 | Antibacterial and antifungal composition comprising vegetation water from Citrus Unshiu |
WO2022220458A1 (en) * | 2021-04-16 | 2022-10-20 | 한국생명공학연구원 | Composition including aurantii fructus immaturus extract as active ingredient for prevention or treatment of male climacteric symptom |
Also Published As
Publication number | Publication date |
---|---|
WO2018062777A1 (en) | 2018-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6682073B2 (en) | Liver function improver | |
KR20180036167A (en) | Composition for increasing muscular strength and muscle mass comprising bean juice-peptides derived from germinated bean treated with green mandarin water | |
KR101449804B1 (en) | Antihypertensive composition comprising gelatin extract from skate skin and peptide isolated from the extract | |
KR102092841B1 (en) | Method for producing cold noodle soup | |
KR20100122296A (en) | Composition containing fermentation tea for improving blood circulation and pharmaceutical composition and health food composition comprising thereof | |
KR20140133016A (en) | Manufacturing methods of Siraitia grosvenorii extracts, and composition comprising the same | |
JP6202697B1 (en) | Method for producing squeezed koji-derived component-containing composition, and method for producing foods and drinks, pharmaceuticals, quasi-drugs, or cosmetics | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101446528B1 (en) | Vinegar Composition Fermented with Black Garlic and Preparation Method Thereof | |
KR101871169B1 (en) | New kimchi lactic acid bacteria Weissella cibaria MFST and composition using concentrated extract of Ziziphus jujuba seed | |
KR101704123B1 (en) | Method for seperating bee venom containing active amines and food composition thereof | |
KR20170124426A (en) | Composition for prevention and treatment of muscular disorders or improvement of muscular functions comprising extract of Amaranthus spp. or grain cereals | |
JP2007230881A (en) | Anti-fatigue composition | |
KR100994196B1 (en) | Method of preparing fermented liquid of garlic and chonggugjang | |
JP2006256969A (en) | Blood flow ameliorant | |
JP2020063302A (en) | Liver function improver | |
JP2019034902A (en) | Composition | |
KR101615819B1 (en) | Manufacturing method pancreatic lipase inhibitor composition using unripe astringent persimmon | |
KR20150002048A (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
KR20190084732A (en) | A composition for improving, preventing and treating obesity comprising fermented pollack skin | |
KR102552886B1 (en) | Composition for preventing and improving obesity, and functional food containing the same | |
KR101434444B1 (en) | Preparation Method for an extract enriched with ginsenoside Rg3 from Ginseng Radix | |
KR101799770B1 (en) | A composition comprising saponin fractions isolated from Platycodon grandiflorum for enhancing exercise capacity | |
KR101350217B1 (en) | Pharmaceutical composition for treating or alleviating obesity or hyperlipidemia comprising black garlic extract and Garcinia cambogia extract | |
KR102649974B1 (en) | Composition for improving muscle function comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |